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scientiﬁc statement “Treatment of Hypertension in the
Prevention and Management of Ischemic Heart Disease: A
Scientiﬁc Statement From the American Heart Association
Council for High Blood Pressure Research and the Coun-
cils on Clinical Cardiology and Epidemiology and Pre-
vention,” published in 2007 (1). A number of important
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2000studies have been published since that date that serve to
modify or at least to further reﬁne the recommendations
of that statement, so an update was considered appro-
priate and timely. Because an AHA/American College of
Cardiology (ACC)/American Society of Hypertension
guideline on the treatment of hypertension in primary
prevention is in process, this document is concerned with
the epidemiology of hypertension and its treatment in
secondary prevention, speciﬁcally in the setting of coro-
nary artery disease (CAD).
Epidemiological studies have established a strong as-
sociation between hypertension and CAD. Hypertension
is a major independent risk factor for the development of
CAD, stroke, and renal failure. The optimal choice of
antihypertensive agents remains controversial, and there
are only partial answers to important questions in the
treatment of hypertension for the prevention and man-
agement of ischemic heart disease (IHD):
 What are the appropriate systolic blood pressure (SBP)
and diastolic blood pressure (DBP) targets in patients
with established CAD?
 Are the beneﬁcial effects of treatment simply a func-
tion of blood pressure (BP) lowering, or do particular
classes of drugs have uniquely protective actions in
addition to lowering BP?
 Are there antihypertensive drugs that have shown par-
ticular efﬁcacy in the secondary prevention of IHD?
 Which antihypertensive drugs should be used in patients
who have established CAD with stable angina pectoris,
in those with acute coronary syndrome (ACS), which in-
cludes unstable angina pectoris (UA), non–ST-segment
elevation myocardial infarction (NSTEMI), and ST-
elevation myocardial infarction (STEMI), and in those
with heart failure (HF) caused by CAD?
This scientiﬁc statement summarizes the published
data relating to the treatment of hypertension in the
context of CAD prevention and management. It attempts,
on the basis of the best available evidence, to develop
recommendations that will be appropriate for both BP
reduction and the management of CAD in its various
manifestations. When data are meager or lacking, the
writing group has proposed consensus recommendations
and has highlighted opportunities for well-designed pro-
spective clinical trials to ﬁll knowledge gaps.
All of the discussion and recommendations refer to
adults. The writing committee has not addressed hyper-
tension or IHD in the pediatric age group. In addition, there
is no discussion of the different modes of assessing BP,
including 24-hour ambulatory BP monitoring. These were
the subject of an AHA scientiﬁc statement in 2005 (2).
Recommendations, with levels of evidence, have
been developed according to the AHA format shown in
Table 1.The general design of the scientiﬁc statement is based
on the concept that each of the clinical sections refers to a
particular subset of patients, so each section should pro-
vide a stand-alone description of the recommendations
and their justiﬁcation independently of the other sec-
tions. This should make it easier for practitioners to
extract the information relevant to any particular patient
without needing to cross-reference, and we hope it will
thereby increase the utility of this document. With this
organization, there may be some repetition of information
from one section to the next, but we have tried to keep
that to a minimum. A summary of the main recommen-
dations is presented in Tables 2 and 3.
1. RELATIONSHIP BETWEEN
HYPERTENSION AND CAD
1.1. Epidemiology of Hypertension and CAD
Hypertension is a major independent risk factor for CAD
for all age/race/sex groups. The Seventh Report of the
Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure (3) uses
the traditional deﬁnition of hypertension as an SBP
of $140 mm Hg or a DBP of $90 mm Hg and/or the current
use of antihypertensive medication. With this deﬁnition,
an estimated 65 million adult Americans, or nearly one
fourth of the adult population of the United States, have
hypertension. Another quarter of the population have
prehypertension, deﬁned as an SBP of 120 to 139 mm Hg
or a DBP of 80 to 89 mm Hg.
The forms of BP elevation differ as a function of age,
with DBP elevation predominating in young hypertensive
individuals and systolic hypertension, often in isolation
(isolated systolic hypertension), emerging in older age.
The prevalence of hypertension is thus directly propor-
tional to the age of the population, with more than one-
half of Americans >65 years of age having a high BP. The
Framingham Heart Study has estimated the remaining
lifetime risk of developing hypertension atz90% for men
and women not yet hypertensive by middle age (4). In
addition, there is a change with age in the relative
importance of SBP and DBP as risk indicators. Before 50
years of age, DBP is the major predictor of IHD risk,
whereas after 60 years of age, SBP is more important (5). It
is important to note that, in this population $60 years of
age, DBP becomes inversely related to CAD risk and pulse
pressure becomes the strongest predictor for CAD. In a
meta-analysis of 61 studies that included almost 1 million
adults (6), BP was related to fatal CAD over the BP range of
115/75 to 185/115 mm Hg for all ages. Overall, each increase
in SBP of 20 mm Hg (or each 10-mm Hg increase in DBP)
doubles the risk of a fatal coronary event.
Epidemiological studies have also shown that an
elevated BP is the most important determinant of the risk
TABLE 1 Applying Classiﬁcation of Recommendations and Levels of Evidence
A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend
themselves to clinical trials. Although randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.
*Data available from clinical trials or registries about the usefulness/efﬁcacy in different subpopulations, such as sex, age, history of diabetes, history of prior myocardial infarction,
history of heart failure, and prior aspirin use.
†For comparative effectiveness recommendations (Class I and IIa; Level of Evidence: A and B only), studies that support the use of comparator verbs should involve direct comparisons
of the treatments or strategies being evaluated.
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2001of stroke. The risk is almost linear, beginning at relatively
low levels of SBP and DBP (7), and the lowering of high BP
is a major factor in the impressive reduction in the stroke
death rates during the last half of the 20th century and the
early part of the 21st century (7,8).
The absolute risk of these adverse outcomes also in-
creases with age. For any given SBP, the risk of fatal CAD
was z16-fold higher for people 80 to 89 years of age than
for those 40 to 49 years of age (5). In the Chicago Heart
Association Detection Project in Industry, men 18 to 39
years of age at baseline with a BP of 130 to 139/85 to
89 mm Hg or with stage 1 hypertension (140–159/90–99
mm Hg) accounted for nearly 60% of all excess IHD,overall cardiovascular disease (CVD), or all-cause mor-
tality (9). Epidemiological data show that lower BP levels
are associated with lower disease risks, suggesting that
future coronary events can be prevented by reducing BP
(10). Elevated BP represents a substantial population-
attributable risk for men and women, both black and
white (11,12).
1.1.1. Effects of Treatment
The risk of CVD in the patient with hypertension
has been shown to be greatly reduced with effective anti-
hypertensive therapy. Major reductions in CVD morbidity
and mortality over the past 50 years have been
TABLE 2 Summary of Pharmacological Treatment of Hypertension in the Management of Ischemic Heart Disease
ACEI or ARB Diuretic b-Blocker Non-DHP CCB DHP CCB Nitrates
Aldosterone
Antagonist
Hydralazine/
Isosorbide Dinitrate
Stable angina 1* 1† 1 2‡ 2 1 2
ACS 1* 1† 1§ 2‡ 2 2 2k
HF 1 1† 1¶ 2 1k 2
*Especially if prior myocardial infarction, left ventricular systolic dysfunction, diabetes mellitus, or proteinuric chronic kidney disease is present.
†Chlorthalidone is preferred. Loop diuretic should be used in the presence of HF (New York Heart Association class III or IV) or chronic kidney disease with glomerular ﬁltration
rate <30 mL $ min1 $ m2. Caution should be exercised in HF with preserved ejection fraction.
‡If b-blocker is contraindicated, a non-DHP CCB can be substituted, but not if left ventricular dysfunction or HF is present. Caution should be exercised if combining a non-DHP CCB
with a b-blocker.
§Esmolol (intravenous) or metoprolol or bisoprolol (oral).
kSpironolactone or eplerenone if left ventricular dysfunction, HF, or diabetes mellitus is present.
¶Carvedilol, metoprolol succinate, or bisoprolol.
ACEI indicates angiotensin-converting enzyme inhibitor; ACS, acute coronary syndrome; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; DHP, dihydropyridine;
HF, heart failure; 1, drug of choice; and 2, “add-on,” alternative drug, or special indications.
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2002attributed to the increased availability and use of drug
treatment for hypertension. Randomized trials have
shown that BP lowering in patients with hypertension
produces rapid reductions in cardiovascular risk (13) that
are highly consistent with data from observational studies.
For example, a 10-mm Hg lower usual SBP (or a 5-mm Hg
lower usual DBP) is associated with a 50% to 60% lower
risk of stroke death and an z40% to 50% lower risk of
death resulting from CAD or other vascular causes at
middle age, beneﬁts that are only slightly smaller in older
people (6). However, in one study, high blood pressure in
the very elderly (>85 years) was not a risk factor for mor-
tality, irrespective of a history of hypertension. Whereas
blood pressure values below 140/70 mm Hg were associ-
ated with excess mortality (14). Likewise, there are in-
consistencies across end points in the older population,
with a signiﬁcant association of lower BP with lower stroke
deaths and HF but not with a lower rate of myocardial
infarction (MI) in patients >80 years of age (15).
Several studies (Heart Outcomes Prevention Evaluation
[HOPE] (16), Survival and Ventricular Enlargement
[SAVE] (17), and European Trial on Reduction of Cardiac
Events With Perindopril in Stable Coronary Artery Dis-
ease [EUROPA]) (18) have shown a beneﬁcial effect of
angiotensin-converting enzyme (ACE) inhibitors on CVD
outcomes in individuals, some hypertensive and someTABLE 3 Summary of BP Goals
BP Goal, mm Hg Condition
Class/Level of
Evidence
<150/90 Age >80 y IIa/B
<140/90 CAD I/A
ACS IIa/C
HF IIa/B
<130/80 CAD IIb/C
Post–myocardial infarction, stroke or TIA,
carotid artery disease, PAD, AAA
IIb/C
AAA indicates abdominal aortic aneurysm; ACS, acute coronary syndrome; BP, blood
pressure; CAD, coronary artery disease; HF, heart failure; PAD, peripheral arterial
disease; and TIA, transient ischemic attack.not, but all with established CVD or at high risk for its
development. However, we do not yet have outcome
studies of treatment of prehypertension in individuals
with BPs in the range of 130 to 139/80 to 89 mm Hg. The
only prospective clinical trial of BP reduction in in-
dividuals with normal BPs is the Trial of Preventing
Hypertension (TROPHY) study (19), in which subjects with
an SBP of 130 to 139 mm Hg or a DBP of 85 to 89 mm Hg
were randomized to be treated for 2 years with either the
angiotensin receptor blocker (ARB) candesartan or placebo
and followed up for an additional 2 years. Hypertension
developed in signiﬁcantly (p < 0.007) more participants in
the placebo group (two thirds of this cohort at 4 years)
than in the candesartan group, with a relative risk reduc-
tion of 66.3% at 2 years and 15.6% at 4 years. In addition,
the treatment of prehypertension with candesartan
appeared to be well tolerated, and serious adverse events
occurred in 3.5% and 5.9% in patients treated with can-
desartan and placebo, respectively. However, the study
was not designed or powered to assess CVD outcomes.
In the Action to Control Cardiovascular Risk in Diabetes
(ACCORD) trial, with a mean follow-up of 4.7 years, a
target BP of <120 compared with <140 mm Hg was not
associated with a reduced risk of a composite of CVD
events (heart attack, a stroke, or a cardiovascular death)
(20). However, the incidence of stroke was signiﬁcantly
less in the intensively treated group.
1.1.2. Risk Factor Interactions
Data from the Framingham Heart Study have provided
evidence of a predictive role of hypertension, dyslipide-
mia, glucose intolerance, cigarette smoking, and left
ventricular (LV) hypertrophy in CVD (21). These 5 primary
risk factors are the most important modiﬁable deter-
minants of CVD risk and appear to operate independently
of one another. This has led to the idea that the threshold
at which a patient should be treated for hypertension
should be determined by a patient’s burden of CVD risk
factors, which in turn determine the level of CVD risk.
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2003In the guidelines developed by the National Kidney
Foundation (22), this principle has been followed for pa-
tients with albuminuria and even modest chronic renal
insufﬁciency, for which the BP threshold for the initiation
of antihypertensive therapy is 130/80 mm Hg. The
American Diabetes Association has based its recommen-
dation on age: People with diabetes mellitus should be
treated to a BP of <140/80 mm Hg, except that “lower
systolic targets, such as <130 mm Hg, may be appropriate
for certain individuals, such as younger patients, if it
can be achieved without undue treatment burden” (23).
Furthermore, there is a correlation between hypertension
and body mass index, with both strongly correlated with
CAD. Hypertension and abdominal obesity are compo-
nents of a larger risk factor constellation of cardiovascular
risk factors, the metabolic syndrome, which also includes
a characteristic form of dyslipidemia (high triglycerides
and low high-density lipoprotein cholesterol) and an
elevated fasting blood glucose level (24).
1.1.3. Risk Factor Reduction
Hypertension, dyslipidemia, diabetes mellitus, cigarette
smoking, obesity, and chronic kidney disease (CKD) are
independent determinants of CVD risk. Moreover, a
diagnosis of peripheral artery disease (PAD) signiﬁcantly
increases the risk for both prevalent and incident disease
in other vascular beds including the coronary and cerebral
circulations (25,26). As indicated previously, hyperten-
sion represents an independent risk factor for CVD, and
evidence indicates that the concomitant presence of other
recognized cardiovascular risk factors results in a multi-
plicative increase in risk for cardiovascular events. Some
current guidelines call for more aggressive BP manage-
ment in the presence of other cardiovascular risk factors,
and BP reduction without attention to other risk factors is
inadequate to reduce cardiovascular risk. Readers should
be aware that several recently published guideline docu-
ments detail the strategies for risk assessment and man-
agement. The recommendations in this document reﬂect
the published guidelines, but readers are advised to con-
sult other recent guidelines such as those on the assess-
ment of cardiovascular risk (27), lifestyle management,
particularly as it relates to diet and exercise (28), and the
management of obesity (29) and dyslipidemia (30).
Cardiovascular risk factors may be described as non-
modiﬁable or modiﬁable. The nonmodiﬁable risk factors of
age, sex, race/ethnicity, and genetic predisposition/family
history are not addressed in this report. The potentially
modiﬁable risk factors include dyslipidemia, diabetes
mellitus, smoking, obesity, PAD, and renal insufﬁciency.
1.1.4. Dyslipidemia
The management of dyslipidemia was the subject of a
recent ACC/AHA guideline (30).In essence, the new guideline does not support
continued use of speciﬁc low-density lipoprotein (LDL)
cholesterol or non–high-density lipoprotein cholesterol
treatment targets. The guideline advocates the use of a
10-year risk calculator to determine the appropriate
intensity of statin therapy to reduce CVD risk in those
most likely to beneﬁt. Those patients with CVD and
age #75 years, with LDL cholesterol $190 mg/dL, or with a
10-year CVD risk $7.5% should receive high-intensity
statin therapy (e.g., atorvastatin 40–80 mg/d or rosuvas-
tatin 20–40 mg/d to reduce LDL cholesterol by approx-
imately $50%). Those with CVD who are >75 years of age
or those with diabetes mellitus but with a 10-year risk
of <7.5% should receive moderate-intensity statin ther-
apy such as simvastatin 20 to 40 mg/d, atorvastatin 10 to
20 mg/d, or rosuvastatin 5 to 10 mg/d to decrease LDL
cholesterol by 30% to 50%.
According to the guideline, nonstatin therapies do not
provide acceptable CVD risk reduction beneﬁts compared
with their potential for adverse effects in the routine
prevention of CVD.
1.1.5. Diabetes Mellitus
Type 2 diabetes mellitus is deﬁned as a fasting plasma
glucose $126 mg/dL, a 2-hour oral glucose tolerance test
value $200 mg/dL, hemoglobin A1C $6.5%, or random
plasma glucose $200 mg/dL in a patient with classic
symptoms of hyperglycemia (23). Type 2 diabetes mellitus
is a strong and independent risk factor for coronary heart
disease. So strong is this association that a diagnosis of
diabetes mellitus could be considered a coronary heart
disease risk equivalent (24), although this is controversial
(31). Hypertensive patients with type 2 diabetes mellitus
are also at increased risk for diabetes mellitus–speciﬁc
complications, including retinopathy and nephropathy.
The pharmacological management of diabetes mellitus
is beyond the scope of this review. Diabetes mellitus care
is complex and requires that many issues, beyond glyce-
mic control, be addressed.
1.1.6. Smoking
There is general consensus that smoking increases the
risk of cardiovascular events. Many studies have shown a
correlation between smoking and death. Life expectancy
is reduced by 13.2 years in male smokers compared with
nonsmokers, and this trend is stronger in female smokers,
with a 14.5-year decrease in life expectancy (32). Cigarette
smoking independently predicts increased risk of cardiac
arrest in patients with CAD (33), and even exposure to
secondhand smoke increases the risk of developing
CAD by 25% to 30% (34). As with other risk factors, there
is a synergistic increase in cardiovascular risk in
smokers who have other, concurrent, cardiovascular risk
factors. Elevated cholesterol confers a higher risk of
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and smokers disproportionately tend toward unfavorable
lipoprotein proﬁles (35). In patients with hypertension,
smokers are 5 times more likely to develop severe hy-
pertension than nonsmokers, and smokers with severe
hypertension have higher mortality rates than non-
smokers (36).
It is encouraging that studies of smoking cessation
demonstrate signiﬁcant long-term reduction (15% over
14 years) in mortality in patients who participate in
smoking cessation activities (37).
1.1.7. Obesity
The prevalence of obesity, deﬁned as a body mass
index $30 kg/m2, has increased in recent years, with
z30% of the adult US population falling into this category
(38). The positive relationship between obesity and BP is
well documented (39–41). Obese adults arez3 times more
likely to be hypertensive compared with nonobese adults
(40–42), and increased adiposity may explain >60% of
hypertension in adults (40). Furthermore, obesity is
considered a major risk factor for poor BP control in
hypertensive patients (3).
Although the mechanisms of obesity-related hyper-
tension are numerous, including activation of the sym-
pathetic nervous system, sodium retention, activation of
the renin-angiotensin-aldosterone system (RAAS), insulin
resistance, and altered vascular function (43), there is no
acceptable guideline on the antihypertensive drug of
choice for the management of hypertension among obese
patients (3,44).
Some investigators consider ACE inhibitors the drugs of
choice for adequate BP control in obesity-related hyper-
tension because of their capacity to increase insulin
sensitivity and thus reduce the risk of diabetes mellitus
(45). This is in contrast to thiazide diuretics, which are
associated with increased risk of diabetes mellitus (46).
That said, the efﬁcacy of thiazide diuretics in lowering BP
and improving cardiovascular outcomes in obese hyper-
tensive patients is well established (47). b-Blockers also
have adverse effects on glucose metabolism but have led
to signiﬁcant improvement in BP in obese hypertensive
patients because they decrease renin activity and cardiac
output, which are often elevated in obese patients (48).
However, enthusiasm for the use of b-blockers as initial
therapy is largely dampened by their negative proﬁle on
stroke outcomes compared with placebo and other anti-
hypertensive drug classes (49).
There is abundant evidence in support of the effec-
tiveness of lifestyle interventions in improving BP control
among obese hypertensive patients. Recently, the AHA,
ACC, and Obesity Society have published guidelines
(29) for the management of overweight and obesity in
adults, including identifying patients who need to loseweight, matching treatment beneﬁts with risk proﬁles,
diets for weight loss, lifestyle intervention and coun-
seling, and the selection of patients for bariatric surgery.
There is also much useful information, particularly on
diet and physical activity, in another AHA/ACC guidelines
document on lifestyle management (28).
1.1.8. Peripheral Artery Disease
Treatment of hypertension in patients with PAD is asso-
ciated with a signiﬁcant reduction in the risk of MI,
stroke, HF, and death. Similarly, intensive management
of LDL is associated with signiﬁcant reduction of cardio-
vascular events in patients with PAD (50). Thus, man-
agement of hypertension in patients with PAD should be
based on intensive screening for and aggressive man-
agement of other concomitant cardiovascular risk factors
in addition to BP reduction (3). Particularly important
in this regard is the management of dyslipidemia, smok-
ing cessation, antiplatelet therapy, diabetes mellitus
management, diet, and exercise.
Currently, there is no recommended drug of choice for
the treatment of hypertension in patients with PAD
because clinical trials of antihypertensive drug agents
such as ACE inhibitors, calcium channel blockers (CCBs),
a-adrenergic blockers, and direct vasodilators have been
largely unsuccessful in improving symptoms of claudica-
tion or walking distance in patients with PAD (51–53).
Although b-blockers constrict resistance vessels, a meta-
analysis concluded that this drug class does not worsen
intermittent claudication in patients with intermittent
claudication (54). Thus, b-blockers can be used in PAD
patients with compelling indications for their use such as
CAD or HF.
The recommendations of the ACC/AHA 2005 practice
guidelines on PAD (55) include the following: 1) Antihy-
pertensive therapy should be administered to hyperten-
sive patients with lower-extremity PAD to achieve a goal
of <140/90 mm Hg (nondiabetics) or <130/80 mm Hg
(diabetics and individuals with chronic renal disease) to
reduce the risk of MI, stroke, congestive HF, and cardio-
vascular death (Level of Evidence: A); 2) b-adrenergic
blocking drugs are effective antihypertensive agents and
are not contraindicated in patients with PAD (Level of
Evidence: A); 3) the use of ACE inhibitors or ARBs is
reasonable for patients with symptomatic (Level of Evi-
dence: B) or asymptomatic (Level of Evidence: C) leg PAD.
1.1.9. Chronic Kidney Disease
There has been a steady increase in the prevalence of
CKD, deﬁned as kidney damage, documented by kidney
biopsy or serum markers for $3 months, or a decrease in
glomerular ﬁltration rate to <60 mL $ min1 $ 1.73 m2 for
$3 months (22). Kidney failure, deﬁned as a glomerular
ﬁltration rate of <15 mL $ min1 $ 1.73 m2, and end-stage
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treatment by replacement therapy (22), afﬂicts >525,000
patients in the United States, 65% of whom are on long-
term hemodialysis (56). Hypertension represents a major
independent risk factor for renal failure, with a preva-
lence of 28% in hypertensive patients (56). In patients
with CKD, cardiovascular death is more likely than pro-
gression to end-stage renal disease, and in patients with
end-stage renal disease, CVD is the leading cause of
death, being 5 to 30 times higher in patients on dialysis
than in the general population (57).
Even in patients with lower stages of CKD, the risk of
CVD is increased independently of other risk factors, and
even the smallest degree of albuminuria increases risk for
CVD and all-cause death (57). In this patient population,
hypertension itself is a leading cause of renal failure. BP
goals in patients with CKD and microalbuminuria are
lower than in the general population (22,58), with a target
the same as that in patients with established CAD. Recent
investigations have demonstrated that standard treat-
ments for cardiovascular risk factors, including statin
therapy, ACE inhibitors, ARBs, and antiplatelet agents,
are equally effective at risk reduction in patients with
CKD (who are not on dialysis) as in those without CKD
and should be offered to this patient population (59).
In these patients, the serum potassium concentration
should be monitored frequently. Questions remain as to
whether directly addressing nontraditional risk factors in
patients with early evidence of renal impairment has
efﬁcacy in terms of outcomes.
1.2. Mechanisms of Hypertension and CAD
A variety of pathophysiological mechanisms contribute to
the genesis of BP elevation and related target-organ
damage, including CAD. These mechanisms include
increased sympathetic nervous system and RAAS activity;
deﬁciencies in the release or activity of vasodilators, for
example, nitric oxide and prostacyclin, and changes in the
natriuretic peptide concentration; increased expression
of growth factors and inﬂammatory cytokines in the
arterial tree; hemodynamic effects; and structural and
functional abnormalities in conductance and resistance
arteries, particularly increased vascular stiffness and
endothelial dysfunction (60). These neurohumoral path-
ways interact with genetic, demographic, and environ-
mental factors (such as heightened exposure or response
to psychosocial stress, excessive dietary intake of sodium,
and inadequate dietary intake of potassium and calcium)
to determine whether a person will develop hypertension
and related CAD. Concomitant metabolic disorders,
for example, diabetes mellitus, insulin resistance, and
obesity, also lead to the production of vasoactive adipo-
cytokines that promote vasoconstriction, endothelial
dysfunction, inﬂammation, and increased oxidative stressin the vasculature, thus increasing both BP and CVD risk
(61,62). These shared pathophysiological mechanisms
offer potential novel therapeutic targets for the preven-
tion and treatment of both hypertension and CAD, with
beneﬁts that may go beyond BP lowering.
1.2.1. Genetics
Genome-wide association studies have identiﬁed multi-
ple genetic susceptibility variants, mostly single-
nucleotide polymorphisms, for atherosclerotic disease
(63). It has been suggested the polymorphisms of genes
of the RAAS, particularly ACE, angiotensin II receptor
type 1, and angiotensinogen, are implicated in the
development of CAD and MI (64,65). The presence of
hypertension further increases the risk of CAD and may
explain why some individuals are more predisposed than
others to developing coronary events. Some poly-
morphisms have also been implicated in the BP response
to antihypertensive treatment. For example, genetic
polymorphisms coding for the matrix metalloproteinases
appear to modify CVD outcomes in hypertensive patients
treated with chlorthalidone, amlodipine, or lisinopril
(66). These data suggest that, in the future, determina-
tion of genetic variants may be of some use for selecting
appropriate antihypertensive agents to reduce both
BP and the risk for CAD. However, because CAD is
polygenic and its causes are multifactorial, genetic
studies explain only a small proportion of the heritability
of the disease (67).
1.2.2. Physical Forces and Hemodynamics
Physical forces (pressure and ﬂow) are the primary
determinants of cardiac structure and function and
inﬂuence coronary arterial remodeling and atheroscle-
rosis. When SBP is elevated, both LV output impedance
and intramyocardial wall tension increase, resulting in
increased myocardial oxygen demand. The wide pulse
pressure and systolic hypertension in older individuals
are usually attributable to inappropriately high aortic
impedance, which results from decreased aortic diameter
or increased effective stiffness caused by aortic wall
thickening and changes in wall composition. Aging is
associated with thinning and fragmentation of vascular
elastin and increased collagen deposition, a degenerative
process that causes increased arterial stiffness (reduction
of elasticity) with an associated elevation in SBP and
widening of the pulse pressure (68–70).
Increased arterial stiffness elevates SBP by increasing
pulse-wave velocity and altering wave reﬂection from the
periphery (68,71–74). With each ejection of blood from the
LV, a pressure (pulse) wave is generated and travels from
the heart to the periphery at a pulse-wave velocity that
depends on the elastic properties of the conduit arteries.
The pulse wave is reﬂected at any point of discontinuity
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2006in the arterial tree and returns to the aorta and LV. The
elastic properties and length of the conduit arteries
determine the timing of the wave reﬂection (73).
In younger people, the pulse-wave velocity is sufﬁciently
slow (z5 m/s) that the reﬂected wave reaches the
aortic valve after closure, leading to a higher DBP and
enhancing coronary perfusion by providing a “boosting”
effect. In older people, particularly those who are
hypertensive, pulse-wave velocity is greatly increased
(z20 m/s) because of central arterial stiffening. Thus,
the reﬂective wave reaches the aortic valve before closure,
leading to the higher SBP, pulse pressure, and afterload
and a lower DBP. The increase in SBP increases cardiac
metabolic requirements and predisposes to the develop-
ment of LV hypertrophy and HF. Pulse pressure is closely
related to SBP and is linked to CVD events, including MI
and stroke. Aortic stiffness is an independent predictor of
all-cause and cardiovascular mortality, fatal and nonfatal
coronary events, and fatal stroke in patients with hyper-
tension, type 2 diabetes mellitus, and end-stage renal
disease (73).
1.2.3. Endothelial Dysfunction
Endothelial dysfunction, characterized by an unfavorable
balance between vasodilators, for example, nitric oxide
and prostaglandin E1, and vasoconstrictors, for example,
endothelin and angiotensin II, is an important contributor
to BP elevation in people with vascular disease. The
injured endothelium loses its vasodilator capacity and
contributes to thrombosis and vascular occlusion. Release
of chemotactic cytokines and adhesion molecules at the
luminal surface of the injured endothelium promotes
adhesion of circulating mononuclear leukocytes to the
vessel wall. This low-grade, self-perpetuating vascular
inﬂammation underlies the atherosclerotic process. In-
ﬂammatory mediators activate medial smooth muscle
cells, causing them to proliferate and migrate into the
subintimal space. In the presence of dyslipidemia,
monocytes in the vessel wall incorporate oxidized low-
density lipoprotein cholesterol and become lipid-laden
macrophages, the core of the atherosclerotic plaque. In
established lesions, resident macrophages secrete metal-
loproteinases and cathepsins, destabilizing the ﬁbrous
cap of the plaque, which may result in plaque rupture and
the release of tissue factor to cause thrombosis, coronary
occlusion, and acute MI.
Endothelial dysfunction and decreased nitric oxide
availability related to mechanical and inﬂammatory
injury of arteries are also associated with increased arte-
rial stiffness and the development of isolated systolic
hypertension (75). A decline in ﬂow-mediated vasodilator
capacity attributable to decreased endothelium-derived
nitric oxide occurs in aging and subclinical vascular dis-
ease (76). Impaired endothelium-mediated vasodilationis responsible for the exaggerated exercise-induced
increases in BP seen in these population groups (77).
1.2.4. Oxidative Stress
Oxidative stress is a critical feature of both hypertension
and atherogenesis (60). In vascular tissue, the principal
effectors of oxidative injury are the NAD(P)H oxidases,
which are activated by mechanical forces (e.g., hyper-
tension), hormones (particularly angiotensin II), oxidized
cholesterol, and cytokines. Several NAD(P)H oxidase
isoforms expressed in endothelial and vascular smooth
muscle cells are upregulated in the setting of athero-
sclerosis and arterial injury. Angiotensin II receptor–
dependent activation of NAD(P)H oxidase stimulates
formation of oxidant superoxide anion (O2), which re-
acts with nitric oxide to form the powerful oxidant
peroxynitrite (ONOO). The resultant reduction in nitric
oxide bioactivity contributes to the vasoconstrictor
response to angiotensin II and elevates BP. Angiotensin
II–induced activation of NAD(P)H oxidase also stimulates
oxidation of low-density lipoprotein cholesterol and
increases the expression of monocyte chemoattractant
protein-1 and vascular cell adhesion molecule-1, thus
linking activation of the RAAS to the atherosclerotic
process.
1.2.5. Humoral and Metabolic Factors
Many of the mechanisms that initiate and maintain
hypertension also damage target organs, including the
coronary arteries and the myocardium. Angiotensin II
elevates BP and promotes target-organ damage, including
atherosclerosis, by mechanisms that include direct effects
on constriction and remodeling of resistance vessels,
stimulation of aldosterone synthesis and release,
enhancement of sympathetic outﬂow from the brain, and
facilitation of catecholamine release from the adrenals
and peripheral sympathetic nerve terminals (1). Aldoste-
rone can mimic or potentiate the vasotoxic properties of
angiotensin II and norepinephrine. Angiotensin II pro-
motes cardiac and vascular smooth muscle cell hyper-
trophy directly via activation of the angiotensin II type 1
(AT1) receptor and indirectly by stimulating expression of
a number of growth factors, cytokines, and adhesion
molecules. AT1 receptor activation also contributes to
endothelial damage and atherogenesis by inhibiting the
mobilization of endothelial progenitor cells from the bone
marrow, thus impairing endothelial regeneration and
vascular repair processes (78). There is also a link between
RAAS activation and ﬁbrinolysis. Angiotensin II induces
the formation of plasminogen activator inhibitor-1 via
an AT1 receptor–dependent effect on endothelial cells,
whereas ACE downregulates tissue plasminogen activator
production by degrading bradykinin, a potent stimulator
of endothelial tissue plasminogen activator expression.
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2007ACE inhibitors and ARBs limit oxidative reactions in
the vasculature by blocking the activation of NAD(P)H
oxidase, supporting the concept that these RAAS
blockers may have important vasoprotective effects
beyond BP lowering (79). Furthermore, there is evidence
of interaction between the RAAS and dyslipidemia: Hy-
percholesterolemia upregulates the RAAS, particularly
vascular AT1 receptor density and functional respon-
siveness, and systemic angiotensin II peptide synthesis
(80,81), whereas the RAAS stimulates the accumulation
of low-density lipoprotein cholesterol in the arterial
wall. These ﬁndings suggest that these antihypertensive
drug classes may have clinically important vaso-
protective effects beyond BP lowering. This hypothesis
has yet to be supported by the results of randomized,
controlled trials (82).
Recent evidence suggests that a second angiotensin II
receptor subtype (AT2), which is not expressed in
the normal vasculature but appears to be induced
in the setting of vascular inﬂammation/hypertension/
atherosclerosis, may oppose the vasoconstrictor, anti-
natriuretic, and proinﬂammatory effects of the AT1 re-
ceptor (83). Because of the apparent vasoprotective
effects of AT2 receptor activation, AT2 receptor agonists
have been considered for the treatment of hypertension
(84), but there is no evidence that they are effective in
treating hypertension in humans.
1.2.6. Calcium
Calcium ions (Ca2þ) are major intracellular mediators of
vascular smooth muscle cell contraction and inotropic and
chronotropic functions of the heart. Ca2þ enters vascular
smooth muscle cells, cardiomyocytes, and pacemaker
cells via voltage-dependent L- and T-type calcium chan-
nels. In vascular smooth muscle, the voltage-gated L-type
(long-acting, slowly activating) channel allows entry
of sufﬁcient Ca2þ for the initiation of contraction by
calcium-induced intracellular Ca2þ release from the sar-
coplasmic reticulum. Increased intracellular Ca2þ also has
atherosclerosis-promoting effects.
The dihydropyridine CCBs bind to the a1 subunit of
the L-type channel and are highly selective for arterial/
arteriolar tissues, including the coronary arteries, where
they are vasodilators. The nondihydropyridine CCBs,
including the phenylalkylamines (verapamil-like) and
benzothiazepines (diltiazem-like), bind to different sites
on the a1 subunit and are less selective for vascular
tissue; they have negative chronotropic and dromo-
tropic effects on sinoatrial and atrioventricular nodal
conducting tissue and negative inotropic effects on
cardiomyocytes. The nondihydropyridine CCBs have
greater effects on the atrioventricular node than on
the sinoatrial node and may predispose to high-degree
atrioventricular block in patients with preexistingatrioventricular nodal disease or when given with other
agents, for example, b-blockers, that depress the atrio-
ventricular node. Both CCB subclasses are indicated for
the treatment of hypertension and angina pectoris.
The antianginal effects of CCBs result from afterload
reduction, that is, their ability to decrease SBP, as well
as coronary vasodilation and, in the case of non-
dihydropyridine CCBs, heart rate slowing. CCBs are
particularly effective in treating angina caused by coro-
nary spasm, for example, the Prinzmetal variant or cold-
induced angina (85).
2. PREVENTION OF CARDIOVASCULAR EVENTS
IN PATIENTS WITH HYPERTENSION AND CAD
2.1. Antihypertensive Drugs for the Secondary Prevention of
Cardiovascular Events in Patients With CAD
Meta-analyses of antihypertensive trials have demon-
strated that BP lowering is more important than the
particular drug class used in the primary prevention of the
complications of hypertension, including IHD. Combina-
tion antihypertensive drug therapy is typically needed to
achieve and to sustain effective long-term BP control.
Thus, there is no evidence to support initiating therapy
with any one antihypertensive drug class over another for
the primary prevention of IHD. In contrast, for secondary
protection in individuals with underlying comorbid
illnesses such as IHD, CKD, or recurrent stroke, not all
drug classes have been proven to confer optimal or even
the same level of beneﬁt.
Whether there are class effects for antihypertensive
drugs and whether each drug should be considered
individually on the basis of trial results are not clearly
known. It is reasonable to assume that there are class
effects for thiazide and thiazide-type diuretics, ACE
inhibitors, and ARBs, which have a high degree of
homogeneity in both their mechanisms of action and side
effects (13,86,87). There are major pharmacological dif-
ferences between drugs within more heterogeneous
classes of agents such as the b-blockers and CCBs (88,89).
Finally, the most recent trials suggest that combining
ACE inhibitors and ARBs is not beneﬁcial for the sec-
ondary prevention of cardiovascular events (90,91),
whereas combinations of renin-angiotensin blocking
agents with thiazide diuretics or with CCBs show impor-
tant clinical beneﬁts (92).
2.1.1. Thiazide and Thiazide-Type Diuretics
Thiazide diuretics and the thiazide-type diuretics
chlorthalidone and indapamide are highly effective
in reducing BP and preventing cerebrovascular events,
as demonstrated most convincingly in early studies
such as the Veterans Administration studies (93), the
Medical Research Council (MRC) Trial (94), the Systolic
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2008Hypertension in the Elderly Program (SHEP) (95), and the
Hypertension in the Very Elderly Trial (HYVET) (15). The
beneﬁt of chlorthalidone-based therapy in hypertension
treatment is evident from the Antihypertensive and
Lipid-Lowering Treatment to Prevent Heart Attack Trial
(ALLHAT) trial (96). Since the publication of the results of
ALLHAT, there have been concerns about whether
thiazide-induced hyperglycemia and diabetes mellitus
contribute to long-term IHD risk not measured during the
study interval (97), but this does not seem to be the case
(98–100).
2.1.2. b-Blockers
b-Blockers make up a heterogeneous class of antihyper-
tensive drugs with differing effects on resistance vessels
and on cardiac conduction and contractility. b-Blocker
administration remains the standard of care in patients
with angina pectoris, those who have had an MI, and
those who have LV dysfunction with or without symp-
toms of HF unless contraindicated. The b-blockers
carvedilol, metoprolol, and bisoprolol have been shown to
improve outcomes in patients with HF (1).
2.1.3. ACE Inhibitors
The ACE inhibitors are effective in reducing initial IHD
events and are recommended for consideration in all pa-
tients after MI. They are proven to prevent and improve
both HF (101,102) and the progression of CKD (103). When
combined with thiazide diuretics, ACE inhibitors reduce
the incidence of recurrent stroke (104). Major trials have
addressed the use of ACE inhibitors in patients with
IHD but without HF or known signiﬁcant LV systolic
impairment.
In the HOPE study (16), 9,297 high-risk patients, of
whom 80% had a history of CAD, were assigned to receive
either ramipril (10 mg once nightly) or placebo and fol-
lowed up for a mean of 5.0 years. Treatment with ramipril
was associated with a 22% reduction in the composite end
point of cardiovascular death, MI, and stroke (p < 0.001)
and comparably signiﬁcant reductions in each of the in-
dividual components. There were also signiﬁcant re-
ductions in the rates of revascularization, cardiac arrest,
HF, worsening angina, and all-cause mortality with ram-
ipril therapy. The mean reduction in the clinic BP with
active treatment was 3/2 mm Hg. These cardiovascular
beneﬁts were initially thought to be independent of BP,
but an interesting but very small HOPE substudy (105)
revealed a more marked reduction in 24-hour ambula-
tory BP with ramipril not observed in the main trial, which
reported only the clinic BPs.
In EUROPA, 12,218 patients were randomized to the
ACE inhibitor perindopril or placebo (18). Although just
27% of patients were classiﬁed as hypertensive, the
deﬁnition of hypertension was based on a clinic BP>160/95 mm Hg or antihypertensive therapy at baseline.
The mean follow-up in EUROPA was 4.2 years. Treat-
ment with perindopril (target dose, 8 mg daily) was
associated with a 20% relative risk reduction in the
composite end point of cardiovascular death, MI, or
cardiac arrest (p < 0.003). The beneﬁt of active treat-
ment with perindopril was similar for patients with or
without hypertension as the investigators deﬁned it. The
mean reduction in BP in the clinic setting was 5/2
mm Hg. At baseline, EUROPA patients were at lower
cardiovascular risk than HOPE patients: One third
were <55 years of age; fewer had diabetes mellitus (12%
versus 39%); and proportionately more EUROPA patients
took antiplatelet (92% versus 76%) and lipid-lowering
(58% versus 29%) drugs.
Patients in the Prevention of Events With Angiotensin
Converting Enzyme Inhibition (PEACE) trial (106) had
stable CAD and normal or slightly reduced LV function
and were randomized to trandolapril (target dose, 4 mg)
or placebo. Median follow-up was 4.8 years. No difference
between the groups was found in the incidence of the
primary composite end point of cardiovascular death, MI,
or coronary artery revascularization. Forty-six percent of
patients were hypertensive, and treatment with trando-
lapril was associated with a mean reduction in BP of 4.4/
3.6 mm Hg. The annualized rate of all-cause mortality in
PEACE was only 1.6%, a rate similar to that of an age- and
sex-matched cohort without IHD. There was a relatively
high use of revascularization before randomization in
the PEACE trial, which may have contributed to the low
event rate.
The investigators concluded that ACE inhibitors might
not be necessary as routine therapy in low-risk IHD
patients with preserved LV function, especially those
who have received intensive treatment with revasculari-
zation and lipid-lowering agents. Thus, 2 large studies in
high-cardiovascular-risk patients (HOPE and EUROPA)
showed cardiovascular protective effects by ACE in-
hibitors, and 1 study in low-cardiovascular-risk patients
(PEACE) did not.
The Ongoing Telmisartan Alone and In Combination
with Ramipril Global Endpoint Trial (ONTARGET) (90)
trial randomized 25,620 patients, of whom 74% had a
history of CAD, to the ACE inhibitor ramipril (10 mg/d), the
ARB telmisartan (80 mg/d), or the combination of these 2
drugs. After a median follow-up of 4.7 years, there was no
difference in the primary outcome of cardiovascular
death, nonfatal MI, nonfatal stroke, and hospitalization
for HF among the 3 groups. In the combination treatment
group, there was an increased risk of hypotensive symp-
toms, syncope, and renal dysfunction compared with
those in the ramipril group. The investigators concluded
that ramipril and telmisartan had similar beneﬁts but
that the combination of the ACE inhibitor and ARB in this
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side effects and no increase in beneﬁt.
2.1.4. Angiotensin Receptor Blockers
Several ARBs have been shown to reduce the incidence or
severity of IHD events, the progression of renal disease in
type 2 diabetes mellitus, and cerebrovascular events.
ARBs are often considered to be an alternative therapy in
individuals with cardiovascular disease who are intol-
erant of ACE inhibitors. In the Valsartan Antihypertensive
Long-term Use Evaluation (VALUE) study, protection
against a composite of cardiovascular events that
included MI and HF was similar to that observed for the
CCB amlodipine (107). However, there were important
differences in BP control in the early stages of the VALUE
trial (a signiﬁcant BP difference in favor of amlodipine)
that may have confounded outcomes for MI and espe-
cially stroke (108).
Beneﬁcial cardiovascular outcomes were not shown in
the Optimal Trial in Myocardial Infarction With the
Angiotensin II Antagonist Losartan (OPTIMAAL) (109).
The lack of beneﬁt may have been attributable to inade-
quate doses of losartan. In the Valsartan in Acute
Myocardial Infarction Trial (VALIANT), the ARB valsartan
had effects similar to those of the ACE inhibitor captopril
in reducing cardiovascular event end points (91). The
combination of the ARB with the ACE inhibitor yielded an
increase in adverse events with no incremental beneﬁt for
cardiovascular events.
In the Telmisartan Randomised Assessment Study in
ACE Intolerant Subjects With Cardiovascular Disease
(TRANSCEND) (110), 5,296 high-risk patients, of whom 75%
had CAD, were randomized to telmisartan (80 mg daily)
or placebo for a median duration of 4.7 years. The mean
BP in the telmisartan group was 4.0/2.2 mm Hg lower
than that in patients randomized to placebo. The primary
outcome of cardiovascular death, nonfatal MI, nonfatal
stroke, and hospitalization for HF occurred in 15.7% of
the telmisartan group and 17.0% of the placebo group
(p ¼ 0.216). The composite of cardiovascular death,
nonfatal MI, and stroke occurred in 13% of patients on
telmisartan versus 14.8% of the placebo group (p ¼ 0.048),
and fewer patients in the telmisartan group had a car-
diovascular hospitalization (30.3% versus 33%; p ¼ 0.025).
The tolerability of telmisartan was similar to that of
placebo. The investigators concluded that telmisartan
had modest beneﬁts on the composite outcome end point
of cardiovascular death, MI, and stroke and was well
tolerated.
2.1.5. Aldosterone Antagonists
The aldosterone antagonists spironolactone and epler-
enone lower BP alone or when added to other antihyper-
tensive agents and have a protective effects in patientswith chronic and advanced HF (in the Randomized Aldac-
tone Evaluation Study [RALES]) (111), in patients with LV
dysfunction after MI (in the Eplerenone Post-Acute
Myocardial Infarction Heart Failure Efﬁcacy and Survival
Study [EPHESUS]) (112), and in patients with chronic HF
and mild symptoms (in the Eplerenone in Mild Patients
Hospitalization and Survival Study in Heart Failure
[EMPHASIS-HF]) (113). In both RALES and EMPHASIS-HF,
the majority of the subjects had IHD.
2.1.6. Calcium Channel Blockers
CCBs form a heterogeneous class of agents that lower BP
but have differing effects on cardiac conduction and
myocardial contractility. In ALLHAT, the primary pre-
vention of cardiovascular events with the dihydropyr-
idine CCB amlodipine was equivalent to that produced by
the diuretic chlorthalidone or the ACE inhibitor lisinopril
(96), and superiority over a b-blocker was claimed in
Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
(114). Primary protection with verapamil-based therapy
was shown to be similar to that of a diuretic (hydrochlo-
rothiazide) or a b-blocker (atenolol) in the Controlled
Onset Verapamil Investigation of Cardiovascular End
Points (CONVINCE) (115) and International Verapamil-
Trandolapril Study (INVEST) (116). In the Nordic Diltia-
zem (NORDIL) study (117), overall cardiovascular event
rates were similar for diltiazem and a combination of
diuretic and b-blocker. Thus, CCBs are alternatives to
b-blockers in the treatment of angina pectoris but are not
recommended for secondary cardiac protection because
of the relative lack of beneﬁt of this class in preventing
HF (118), particularly compared with ACE inhibitors (96)
or ARBs (107).
2.1.7. Direct Renin Inhibitors
The direct renin inhibitor aliskiren lowers BP alone or
when added to other antihypertensive agents but has not
been shown to have protective effects in patients with
CVD, including HF (119). In 2011, the Aliskiren Trial In
Type 2 Diabetes Using Cardio-Renal Disease Endpoints
(ALTITUDE) was stopped on the recommendation of
its Data Monitoring Committee (119). ALTITUDE was
comparing placebo with aliskiren 300 mg once daily
added to background ACE inhibitor or ARB therapy in
patients with diabetes mellitus and either increased uri-
nary albumin excretion or both a reduced estimated
glomerular ﬁltration rate and established CVD. The pri-
mary outcome in ALTITUDE was a composite of cardio-
vascular death, resuscitated sudden death, nonfatal MI,
nonfatal stroke, hospitalization for HF, end-stage renal
disease, renal death, or doubling of baseline serum
creatinine concentration, sustained for at least a month.
The basis for stopping the trial was futility for
success and safety concerns, including renal dysfunction,
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number of patients experiencing a nonfatal stroke in the
placebo group was 85 (2.0%) and in the aliskiren group
was 112 (2.6%; unadjusted p ¼ 0.04). Given prior data
relating the use of antihypertensive therapy to a reduced
incidence of stroke in patients with diabetes mellitus, it is
possible that the imbalance in strokes represents a
chance ﬁnding. Nevertheless, the general recommenda-
tion at present is to avoid the use of aliskiren in combi-
nation with another renin-angiotensin blocking agents
in patients with hypertension for the primary prevention
of CVD.
3. BP GOALS
3.1. Epidemiology and Coronary Physiology
The overall goal of therapy is to reduce excess morbidity
and unnecessary deaths. In the case of hypertension,
dyslipidemia, and diabetes mellitus, surrogate end points
(BP, cholesterol, and blood glucose) have been estab-
lished as diagnostic markers, and discrete values of these
markers have been established as therapeutic targets. A
commonly cited target for BP is <140/90 mm Hg in gen-
eral and <130/80 mm Hg in some individuals with dia-
betes mellitus or CKD (3,22,23). The ﬁrst AHA scientiﬁc
statement on the treatment of hypertension in the pre-
vention and management of IHD also recommended a
goal of <130/80 mm Hg in individuals with established
CAD, with CAD equivalents, or with a Framingham Risk
Score of $10% (1).
Some recent meta-analyses have suggested that the
lower BP target for higher-risk patients is not supported
by evidence from high-quality, randomized, clinical tri-
als (120–122). Whether the lower BP goal is appropriate
for the prevention of coronary disease and for the
treatment of established coronary disease is the subject
of intense debate. There is a historical trend for lower
BP goals, especially in those with target-organ damage.
Controversy remains, however, about speciﬁc BP treat-
ment goals for individuals with nascent or overt CAD.
On the one hand, it can be argued from pathophysio-
logical principles that very low SBP values (i.e., <120
mm Hg) may be appropriate to reduce myocardial work-
load (123). At the same time, there is a concern that
excessive lowering of DBP may impair coronary perfusion.
At present and despite the ACCORD study (20), discussed
below, there is no consensus on the question of what
the most appropriate BP target(s) should be in individuals
with latent or overt CAD or prominent CAD risk factors.
We believe, however, that reasonable recommendations
can be developed from a synthesis of the results
from relevant epidemiological studies, consideration of
the theoretical issue of the J curve, data from animal
studies, human studies involving surrogate end points,and randomized, clinical trials targeting different BP goals
with cardiovascular events as end points.
3.1.1. Epidemiological Studies
Although epidemiological correlations cannot be used as
proof of the value of treatment, they are useful in
establishing expectations for reasonable treatment stra-
tegies. More speciﬁcally, epidemiological data do not
necessarily predict cardiovascular outcomes when BP is
lowered as a result of antihypertensive treatment.
Nevertheless, population studies such as the Prospective
Studies Collaboration (6), the Framingham Heart Study
(124), the Women’s Health Initiative (125), and the
Hisayama Study (126) in Japan provide some support for
a “lower is better” strategy for BP control. The debate
about lower BP targets revolves around the issue of
the so-called J curve and, more speciﬁcally, whether
lower BP targets are appropriate or even safe for patients
with CAD.
3.1.2. Coronary Perfusion, Autoregulation, and the J Curve
Many studies demonstrate that lowering SBP, DBP, or
both decreases overall cardiovascular risk. Yet, concern
has persisted that excessive DBP lowering may have
adverse consequences for the heart. In virtually all
instances, lowering SBP improves cardiac function and
outcomes, probably through a reduction in cardiac work
and an improved myocardial oxygen balance. On the
other hand, it is theoretically possible that lowering of
DBP improves cardiovascular outcomes only when coro-
nary perfusion is maintained above the lower limit of
coronary autoregulation.
Myocardial perfusion occurs almost exclusively dur-
ing diastole; therefore, DBP is the coronary perfusion
pressure. Like most vascular beds, the coronary circu-
lation is capable of autoregulation, so that a decrease in
perfusion pressure is accompanied by coronary vasodi-
lation, which maintains a fairly constant coronary
blood ﬂow. The problem is that this ability of coronary
resistance vessels to dilate in response to a falling
perfusion pressure is limited, and at the point of
maximal vasodilation, a further decrease in coronary
perfusion pressure will result in a decrease in ﬂow. In
conscious, instrumented dogs, contractile function
(transmural wall thickening and subendocardial
segment shortening) is well maintained at mean coro-
nary ﬁlling pressures down to 40 mm Hg, which cor-
responds to a DBP of z30 mm Hg (127–129). The lower
limit of autoregulation in dogs with LV hypertrophy is
shifted upward by z15 to 20 mm Hg but can be
partially restored by ACE inhibition, with accompanying
regression of LV hypertrophy (129). These studies were
in dogs with normal intramural coronary arteries.
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human coronary circulation.
In the presence of occlusive CAD, the hemodynamics
are much more complicated. Signiﬁcant CAD will shift the
lower autoregulatory limit upward. However, because
myocardial blood ﬂow is very heterogeneous (130), the
consequences of coronary underperfusion are unpredict-
able and may depend on intramyocardial wall stress
(which in turn is increased by a high arterial pressure but
decreased by LV hypertrophy), the effects of antihyper-
tensive medications on these variables, and, of course,
the severity of the occlusive coronary disease.
There is also a reduced coronary ﬂow reserve (deﬁned
as the difference between resting ﬂow and ﬂow through
a maximally dilated coronary circulation at any level of
perfusion pressure) in patients with LV hypertrophy,
coronary atherosclerosis, or microangiopathy, with a
reduced functional or structural capacity of coronary
resistance vessels to dilate (131). This potential for
impairment of myocardial oxygen supply may be com-
pounded by an increased myocardial oxygen demand
resulting from exercise, LV hypertrophy, and the in-
crease in the output impedance of the LV caused by the
increased SBP. This combination of a decreased oxygen
supply and an increased oxygen demand, especially
during exercise, is particularly pernicious in the heart
because the heart is an aerobic organ that can develop
only a small oxygen debt, and oxygen extraction is
almost maximal even at rest and can increase little with
increased demand.
It is theoretically possible, therefore, that although
lowering BP improves cardiovascular outcomes in hy-
pertensive patients (as long as coronary perfusion is
maintained above the lower autoregulatory limit for
coronary blood ﬂow), any further reduction of DBP to
levels below the lower autoregulatory limit could
reduce coronary blood ﬂow. This could be translated to
an upturn in the incidence of coronary events as DBP is
lowered beyond this point, especially when myocardial
oxygen consumption is increased such as during exer-
cise. The relationship between DBP and coronary events
would, if this were true, show a J-shaped curve. A
major difﬁculty is that we do not have data on the DBP
level that corresponds to the lower limit of autor-
egulation in the human coronary circulation, in healthy
individuals, or in patients with hypertension and CAD.
It would also be reasonable to assume that a rapid
reduction in DBP to very low levels may be more haz-
ardous in patients with combined hypertension and
CAD, although we have no experimental or clinical trial
evidence to support this idea. We therefore must rely
on clinical studies with surrogate end points and the
few relevant clinical trials with outcomes data to
attempt to resolve this issue.3.2. Clinical Studies
3.2.1. Lower BP With a Surrogate Outcome
An analysis of the 274 patients with CAD who completed
the intravascular ultrasound substudy of the Comparison
of Amlodipine Versus Enalapril to Limit Occurrences of
Thrombosis (CAMELOT) trial (132) showed that those
subjects with a normal BP according to the deﬁnition
given in the Seventh Report of the Joint National Com-
mittee on Prevention, Detection, Evaluation, and Treat-
ment of High Blood Pressure (3) (<120/80 mm Hg) had a
mean decrease in coronary atheroma volume of 4.6 mm3,
prehypertensive (120–139/80–89 mm Hg) subjects had no
signiﬁcant change, and hypertensive ($140/90 mm Hg)
subjects had a mean increase in atheroma volume of 12.0
mm3. The authors concluded, “This study suggests that in
patients with CAD, the optimal BP goal may be substan-
tially lower than the <140/90 mm Hg level.” The results of
CAMELOT can be taken only as hypothesis generating
because the effect of achieved BP on atheroma volume
was not a prespeciﬁed outcome. Because this was a post-
hoc analysis, there is the potential for residual con-
founding effects, especially because the individuals in the
higher BP cohort were older and were more likely to have
been assigned to the placebo arm of the study and
therefore not treated with either amlodipine or enalapril.3.2.2. Observational Studies and Clinical Trials
If coronary autoregulation were clinically important, it
would be predicted that a U-shaped or J-shaped rela-
tionship should exist between DBP and CAD events.
Furthermore, the presence of structural CAD could be
expected to affect the pressure-ﬂow relationships in the
coronary arteries, with a lower tolerance of diastolic
pressures. There is evidence from clinical trials to both
support and refute the existence of a J curve.
The ﬁrst retrospective study in 1979 reported a 5-fold
increase in MI among treated patients with DBP (Korotk-
off phase IV) values <90 mm Hg (133), roughly equivalent
to <80 to 85 mm Hg using the more universal Korotkoff
phase V. This observation was conﬁrmed by a subsequent
meta-analysis in 1987 (134) and a reanalysis of the
1985 MRC trial of mild hypertension, which reported
an increased MI prevalence in those with achieved
DBP <80 mm Hg (135). However, other investigators using
the same data have drawn opposite conclusions about
whether a J curve really exists (136,137).
A secondary analysis of data from INVEST (138,139) of
patients with known CAD and hypertension showed a
J-shaped relationship between BP and the primary out-
come (all-cause death, nonfatal stroke, and nonfatal MI),
all-cause death, and total MI, with a nadir at 119/84
mm Hg. This was not the case for stroke. These post hoc
results were also cited in an analysis by Thune et al (140)
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existence of a J curve and a warning against excessive
lowering of BP. However, what was not mentioned was
that patients in that trial who had a BP <120/70 mm Hg
(the level below which the risk of adverse outcomes
seemed to rise) were older and had a history of more MI,
coronary artery bypass grafting or percutaneous coronary
intervention, stroke or transient ischemic attack, diabetes
mellitus, HF, and cancer, all confounding factors. After
adjustment for these and other comorbidities, there was
no increased risk down to a DBP of 50 mm Hg (139).
A different nadir for a J-shaped relationship of BP with
outcome, 146.3/81.4 mm Hg, was identiﬁed in another
secondary analysis, this time of the Treating to New
Targets Trial (TNT) in patients with clinically evident CAD
(142). The Secondary Manifestations of Arterial Disease
(SMART) study of patients with manifest arteriosclerotic
disease had a nadir of 143/82 mm Hg (143). The implica-
tion of these trials is that there is a higher risk of coronary
events if the SBP is <146.3 or 143 mm Hg, which is clearly
at odds with the mass of data from clinical trials over
many decades, which show that SBPs <140 mm Hg are
cardioprotective.
There are much debate and disagreement about the
methodological assumptions and pitfalls, and several
reports have articulated how confounding variables,
especially age and comorbidities, including late-stage
HF, could have affected the conclusions (144–147). In
none of the retrospective analyses was it possible to
control adequately for the many interacting comorbid
conditions that accompany and confound low DBP or
for the complex relationships among age, DBP, and CVD
risk. Age, DBP, and cardiovascular risk are positively
associated until z50 years of age. For the remainder of
life, DBP decreases and pulse pressure widens, whereas
cardiovascular risk increases exponentially. Age is by far
the most important risk factor for CAD; the prevalence
of fatal ischemic cardiac events increases by 64-fold as
age doubles from 40 to 80 years. However, a high SBP,
a low DBP, and a wide pulse pressure are each inde-
pendent risk factors for CAD, but SBP was a better
predictor of outcomes than pulse pressure (5,148,149).
Thus, the effects of a low DBP or wide pulse pressure
cannot be separated easily from those of aging in pre-
dicting the risk of a fatal MI. This important confounder
may explain much of the confusion over the existence
of a J curve in observational studies.
These results suggest that wide pulse pressure is a
signiﬁcant determinant of whether the DBP is a major
risk predictor. Therefore, in those studies that reported
a J curve, possible explanations include diminished
myocardial perfusion during diastole, an age-related
increase in pulse pressure reﬂecting stiffer large
arteries, or an epiphenomenon related to a known orundetected underlying illness (e.g., cancer, HF), so-
called reverse causality in which the pre-existing
illness explains both the low BP and the high risk
of death.
There is also direct evidence against the concept of the
J curve. For example, in the CAMELOT trial (150), 1,991
patients had angiographically documented CAD, and the
mean entry BP was 129/77 mm Hg. Treatment with either
an ACE inhibitor or a CCB lowered BP by an additional
5/2 mm Hg, with no evidence of a J-curve in either treated
group.
3.2.3. Clinical Trials to Speciﬁcally Evaluate Lower BP Goals
Data from controlled trials designed primarily to evaluate
lower BP goals in hypertensive subjects have not shown a
J curve.
Population-based studies suggest that z45% of white
adults with diabetes mellitus have coronary heart disease
compared with 25% in nondiabetic individuals (151).
This makes the ACCORD study relevant to the issue
of BP targets in patients with CAD. ACCORD was a trial
to evaluate the overall effects of intensiﬁed glycemic
control, intensive BP lowering, and reduced triglyceride
levels in patients with type 2 diabetes mellitus and
other risk factors for CVD. The BP study (20) random-
ized 4,733 patients, of whom 34% had had a previous
cardiovascular event, to an intensive therapy arm, with
an SBP target of <120 mm Hg, or to standard therapy,
targeting an SBP of <140 mm Hg. After 1 year, the mean
SBP was 119.3 mm Hg in the intensive therapy group,
and 133.5 mm Hg in the standard therapy group, a dif-
ference of 14 mm Hg. During the mean follow-up of 4.7
years, there was no signiﬁcant difference between the 2
groups with respect to the primary composite outcome
(nonfatal MI, nonfatal stroke, or death resulting from
cardiovascular causes), nonfatal MI, all-cause mortality,
cardiovascular death, major coronary disease event, or
fatal or nonfatal HF. However, the risk of the primary
composite end point was numerically lower (by 12%) in
those randomized to the lower goal. Similarly, the risk
of MI was lower (by 13%) in the group randomized to
the lower BP target, but this was not statistically sig-
niﬁcant. There was a putatively signiﬁcantly lower
incidence of stroke in the intensive therapy group (i.e.,
uncorrected for multiple comparisons), but the number
of strokes was small (at 98). The main conclusion drawn
by the investigators from this study is that an SBP <120
mm Hg in patients with type 2 diabetes mellitus is not
justiﬁed (20,152). In the context of the J-curve conun-
drum discussed above, it is worthwhile noting that the
mean achieved DBP in the intensive therapy group at 4
to 8 years after randomization was in the range of 60 to
65 mm Hg and that there was not only no signiﬁcant
increase in coronary events at these DBPs but in fact a
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together with the signiﬁcant protection from stroke,
seen in ACCORD and most other trials could suggest a
different interpretation of the ACCORD results, namely
that lower DBPs are safe, at least in the range of 60 to
65 mm Hg, and may protect against stroke. The Systolic
Blood Pressure Intervention Trial (SPRINT), now
underway, has a trial design very similar to that of
ACCORD but has enrolled only nondiabetic subjects,
with a heavy representation of the elderly and patients
with CKD.
3.2.4. Lower BP Goals and Diabetes Mellitus
Besides the ACCORD study, discussed above, there have
been other studies relevant to secondary prevention of
cardiovascular events in patients with hypertension and
CAD. In a diabetic cohort of subjects with hypertension
and CAD in INVEST (116), tight control of SBP (<130
mm Hg) was not associated with improved cardiovas-
cular outcomes compared with usual control (130–
139 mm Hg), although in an extended follow-up of
z9 years, the risk of all-cause mortality was 22.8%
versus 21.8%, respectively, which was just statistically
signiﬁcant. This is a small difference, and it is uncertain
whether this can be regarded as a contribution to
clinical decision making.
In the earlier Appropriate Blood Pressure Control in
Diabetes (ABCD) trial, the mean BP achieved was 132/78
mm Hg in the intensive group and 138/86 mm Hg in the
moderate BP control group. After 5 years, there was no
difference between the groups in the progression of
diabetic microvascular complications or in the rate of
MI, stroke or HF. However, unlike the result in INVEST,
the ABCD participants in the intensive group had a
signiﬁcant reduction in all-cause mortality (153).
The latest standards of medical care in diabetes
mellitus (2013) (23) of the American Diabetes Association
recommend a goal BP of <140/80 mm Hg; lower
values, <130/80 mm Hg, “may be appropriate for certain
individuals, such as younger patients, if it can be ach-
ieved without undue treatment burden.”
3.2.5. Lower BP Goals for the Prevention of Stroke
Patients with atherosclerotic stroke should be included
among those deemed to be at high risk ($20% over
10 years) of further atherosclerotic cardiovascular
events (154).
Besides ACCORD, in which there was no excess MI
from intensive BP lowering and some beneﬁt in prevent-
ing stroke, there have been other studies in which the
effects of BP lowering on stroke outcomes have been
documented. With 1 exception, the reports are consistent
with supporting better stroke outcomes with BPs <130/
80 mm Hg.The exception is a post hoc observational analysis of
the Prevention Regimen for Effectively Avoiding Second
Strokes (PROFESS) data, involving 20,330 patients with
recent ischemic stroke. Hypertension was not an in-
clusion criterion, although most of the patients had
elevated BP. PROFESS was also not a clinical trial of
antihypertensive therapy but primarily of antiplatelet
agents. During the 2.5 years of follow-up, the adjusted
hazard ratio for subjects with an SBP in the 120- to
129-mm Hg range, compared with those in the 130- to
139-mm Hg range, was 1.10 (95% conﬁdence interval,
0.95–1.28) for stroke and 1.01 (95% conﬁdence interval,
0.64–1.89) for fatal stroke, both not statistically sig-
niﬁcant, and 1.16 (95% conﬁdence interval, 1.03–1.31)
for a composite end point of stroke, MI, or vascular
death (155).
In a very large meta-analysis of 147 randomized trials of
antihypertensive therapy (156), the percentage reductions
in coronary heart disease events and stroke were similar
in people with and without CVD and regardless of BP
before treatment (down to 110 mm Hg SBP and 70 mm Hg
DBP). A meta-regression analysis that included 31 inter-
vention trials of BP lowering in z74,000 patients with
diabetes mellitus reported a decrease of 13% in the risk of
stroke for each 5-mm Hg reduction in SBP and of 11.5% for
each 2-mm Hg reduction in DBP. In contrast, the decrease
in the risk of MI approached but did not achieve statistical
signiﬁcance (157).
In ONTARGET, the beneﬁts from lowering SBP to <130
mm Hg were driven mostly by a reduction in stroke.
MI was unaffected and cardiovascular mortality was
unchanged (90).
There is consistency in these reports, namely that
intensive BP lowering to <130/80 mm Hg does not
signiﬁcantly decrease or increase coronary morbidity or
mortality but may be protective against stroke. However,
the PROFESS data are different, so the issue is still
somewhat moot.
3.2.6. The Elderly
It might be predicted that a J curve would have a more
devastating effect on elderly individuals, with a nadir at
higher pressures, because of the greater likelihood of their
having CAD and a lower coronary reserve. Very few
studies have addressed this question, but those that have
addressed it have produced reasonably reassuring results.
An INVEST substudy (158) showed a J-shaped relationship
between DBP and the primary outcome (all-cause death,
nonfatal MI, or nonfatal stroke) but with a nadir of 75
mm Hg, except for the very old, for whom it was even
lower at 70 mm Hg. In HYVET (15), patients >80 years of
age with a mean BP of 173.0/90.8 mm Hg were random-
ized to receive treatment with indapamide, with peri-
ndopril added if necessary, versus placebo. In the active
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and produced a 30% reduction in stroke and a 64%
reduction in HF but had no signiﬁcant effect on MI. The
HYVET authors stated, “The results support a target BP
of 150/80 mm Hg in patients receiving treatment, since
that target was reached in nearly 50% of such patients in
HYVET after 2 years (15)”.
With regard to the 65- to 79-year range, we take note of
the recommendation of the ACC Foundation/AHA 2011
expert consensus document on hypertension in the
elderly (159), which states: “The general recommended
goal BP in people with uncomplicated hypertension
is <140/90 mm Hg. However, this target for elderly pa-
tients with hypertension is based on expert opinion rather
than on data from RCTs [randomized, controlled trials],
and it is unclear whether the target SBP should be the
same in 65 to 79 year old versus older patients.” We have
therefore retained a target of <140/90 mm Hg for this age
group.
3.2.7. Conclusions
Lower SBP values may be associated with better stroke
outcomes except in the case of PROFESS, and the
evidence for CAD outcomes is equivocal. The evidence
that excessive lowering of DBP may compromise car-
diac outcomes (the J curve) is inconsistent. Epidemio-
logical and clinical trial evidence both support and
refute the existence of a J curve for DBP but not SBP,
which suggests the presence of major confounders of
data interpretation, including selection bias, comorbid-
ities, and nonlinear interactions among age, decreasing
DBP, and increasing cardiovascular risk. The vast ma-
jority of hypertensive individuals, including those with
overt cardiac disease, will not experience problems
related to lowering of DBP when standard antihyper-
tensive medications are used. Concerns that coronary
perfusion is limited by an autoregulatory threshold
have not yet been validated in humans with healthy or
even diseased coronary arteries, and no consensus
exists on the minimum safe level of DBP in these in-
dividuals. Although an autoregulatory threshold has
not been deﬁned in humans, with or without CAD, it is
clear, mainly from ACCORD, that lower BP targets,
down to levels <120/80 mm Hg, protect against stroke
and do not signiﬁcantly increase CAD events. Most
studies that have addressed lower BP targets have
achieved DBP values in the 70- to 79-mm Hg range,
which appears to be safe.
Therefore, a reasonable recommendation would be a
BP target of <140/90 mm Hg for the secondary prevention
of cardiovascular events in patients with CAD. However,
there are some epidemiological data, several post hoc
analyses of clinical trials, and a plethora of other data
that support, but do not prove, that a lower target(<130/80 mm Hg) may be appropriate in some individuals
with CAD. We counsel that the BP should be lowered
slowly in patients with occlusive CAD with evidence of
myocardial ischemia, and caution is advised in inducing
decreases in DBP to <60 mm Hg, particularly if the patient
is >60 years of age. In older hypertensive individuals with
wide pulse pressures, lowering SBP may cause very low
DBP values (<60 mm Hg). This should alert the clinician
to assess carefully any untoward signs or symptoms,
especially those resulting from myocardial ischemia. In
patients >80 years of age, a reasonable BP target is <150/
80 mm Hg, although there are no direct data to support
this, or any other speciﬁc BP goal, in this age group.
3.3. Recommendations
1. The <140/90-mm Hg BP target is reasonable for
the secondary prevention of cardiovascular events in
patients with hypertension and CAD (Class IIa; Level
of Evidence: B).
2. A lower target BP (<130/80 mm Hg) may be appro-
priate in some individuals with CAD, previous MI,
stroke or transient ischemic attack, or CAD risk
equivalents (carotid artery disease, PAD, abdominal
aortic aneurysm) (Class IIb; Level of Evidence: B).
3. In patients with an elevated DBP and CAD with
evidence of myocardial ischemia, the BP should be
lowered slowly, and caution is advised in inducing
decreases in DBP to <60 mm Hg in any patient with
diabetes mellitus or who is >60 years of age. In
older hypertensive individuals with wide pulse pres-
sures, lowering SBP may cause very low DBP values
(<60 mm Hg). This should alert the clinician to assess
carefully any untoward signs or symptoms, especially
those resulting from myocardial ischemia (Class IIa;
Level of Evidence: C).
4. MANAGEMENT OF HYPERTENSION IN
PATIENTS WITH CAD AND STABLE ANGINA
The management of hypertension in patients with chronic
CAD and chronic stable angina is directed toward the
prevention of death, MI, and stroke; a reduction in
the frequency and duration of myocardial ischemia;
and the amelioration of symptoms. Lifestyle changes and
the adoption of a heart healthy approach are critical, with
the usual attention to diet, sodium intake, moderation of
alcohol intake, regular exercise, weight loss, smoking
cessation, glycemic control, lipid management, and anti-
platelet therapy. Recognition and treatment of hypothy-
roidism and obstructive sleep apnea are important
adjuncts in at-risk patients. Pharmacological management
is inevitably required.
A reasonable BP target for hypertensive patients with
demonstrated CAD is <140/90 mm Hg (20,155,159–167).
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some individuals with CAD or those with previous MI,
stroke or transient ischemic attack, or CAD risk equi-
valents (carotid artery disease, PAD, abdominal aortic
aneurysm).
4.1. Pharmacological Therapy
4.1.1. b-Blockers
b-Blockers are the drugs of ﬁrst choice for the treatment
of hypertension in patients with CAD that causes angina
(168,169). They alleviate ischemia and angina primarily
as a function of their negative inotropic and chrono-
tropic actions. The decreased heart rate increases dia-
stolic ﬁlling time for coronary perfusion. b-Blockers also
inhibit renin release from the juxtaglomerular appa-
ratus. Cardioselective (b1) agents without intrinsic
sympathomimetic activity are used most frequently.
Relative contraindications to their use include signiﬁ-
cant sinus or atrioventricular node dysfunction, hypo-
tension, decompensated HF, and severe bronchospastic
lung disease.
PAD is rarely made symptomatically worse by the use
of these agents, and mild bronchospastic disease is not an
absolute contraindication. Caution is needed when brittle
diabetic patients with a history of hypoglycemic events
are treated because b-blockers may mask the symptoms of
hypoglycemia.
Recently, there has been considerable controversy
concerning the appropriateness of using b-blockers as
ﬁrst-line therapy in hypertension in those patients who
do not have a compelling indication; however, their use
in patients with angina, prior MI, or HF has a solid basis
of positive data. b-Blockers should be prescribed as
initial therapy for the relief of symptoms in patients
with stable angina. b-Blockers may be considered as
long-term therapy for all other patients with coronary
or other vascular disease. Recent ACC Foundation/AHA
guidelines (169,170) have recommended b-blocker ther-
apy in patients with normal LV function after MI or ACS
(Class I; Level of Evidence: B), speciﬁcally carvedilol,
metoprolol succinate, or bisoprolol, in all patients with
LV systolic dysfunction (ejection fraction #40%) or with
HF or prior MI unless contraindicated (Class I; Level
of Evidence: A). b-Blockers should be started and
continued for 3 years in all patients with normal LV
function after MI or ACS (Class I; Level of Evidence: B)
(168–170).
4.1.2. Calcium Channel Blockers
As a class, CCBs reduce myocardial oxygen demand by
decreasing peripheral vascular resistance and lowering BP
and increase myocardial oxygen supply by coronary
vasodilation. The nondihydropyridine agents diltiazemand verapamil also decrease the sinus node discharge rate
and slow atrioventricular nodal conduction.
CCBs or long-acting nitrates should be prescribed for
the relief of symptoms when b-blockers are contra-
indicated or cause unacceptable side effects in patients
with stable angina (Class IIa; Level of Evidence: B)
(168). CCBs or long-acting nitrates in combination with
b-blockers should be prescribed for the relief of symptoms
when initial therapy with b-blockers is unsuccessful in
patients with stable angina (Class IIa; Level of Evidence:
B) (168). CCBs are added to, or substituted for, b-blockers
when BP remains elevated, when angina persists, or when
drug side effects or contraindications mandate (171).
Long-acting dihydropyridine agents are preferred over
nondihydropyridines (diltiazem or verapamil) for use in
combination with b-blockers to avoid excessive brady-
cardia or heart block. Diltiazem or verapamil should not
be used in patients with HF or LV systolic dysfunction
(171), and short-acting nifedipine should be avoided
because it causes reﬂex sympathetic activation and
worsening myocardial ischemia (169).
Although CCBs are useful in the management of
hypertension in patients with stable angina, there is no
consensus about their role in preventing cardiovascular
events in patients with established CAD. The INVEST
investigators randomized >22,000 hypertensive patients
with chronic CAD to the nondihydropyridine CCB verap-
amil or the b-blocker atenolol (116). By 24 months, the
ACE inhibitor trandolapril had to be added in 63% of
verapamil patients and 52% of atenolol patients, and hy-
drochlorothiazide was added in 44% of verapamil and
60% of atenolol patients. There was no difference
between the groups in the composite end point of death,
MI, or stroke over a mean follow-up of 2.7 years. More
than 50% of patients in ALLHAT had a history or signs of
atherosclerotic vascular disease, and there was no sig-
niﬁcant difference in the incidence of coronary end points
among patients allocated a thiazide-type diuretic, a long-
acting dihydropyridine CCB, or an ACE inhibitor (96).
CAMELOT compared amlodipine or enalapril with placebo
in normotensive patients with CAD,z60% of whom had a
history of hypertension (150). Although the BP reduction
was similar in the 2 active treatment groups, adverse
cardiovascular events occurred less frequently in the
amlodipine group than in the enalapril group. An intra-
vascular ultrasound substudy of CAMELOT showed
progression of atherosclerosis in the placebo group
(p < 0.001), a trend toward progression in the enalapril
group (p ¼ 0.08), and no progression in the amlodipine
group (p ¼ 0.31). Amlodipine may have pleiotropic effects
beyond BP lowering that favor atherosclerotic plaque
stabilization (172,173).
The VALUE trial randomized 15,245 hypertensive
patients at high risk of cardiac events to valsartan or
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groups had CAD. Mean follow-up was 4.2 years. No dif-
ference between groups was observed in the primary
composite end point of cardiac morbidity and mortality.
The risk of MI was lower in the amlodipine group,
whereas the risk of new-onset diabetes mellitus was lower
in the valsartan group. Of note, amlodipine was signiﬁ-
cantly more effective in reducing BP, especially over the
ﬁrst year of the trial. There was also a strong trend for an
excess risk of stroke in the valsartan group, likely
resulting from this same BP differential that favored
amlodipine. The investigators highlighted the need for
aggressive BP control in high-risk hypertensive patients, a
goal that frequently requires combination therapy at the
outset, a concept supported by the Blood Pressure
Lowering Treatment Trialists’ Collaboration (174).
4.1.3. ACE Inhibitors
ACE inhibitors should be prescribed to all CAD patients
with stable angina who also have hypertension, diabetes
mellitus, an LV ejection fraction #40%, or CKD unless
contraindicated (Class I; Level of Evidence: A) (169). The
clinical trials that support the use of ACE inhibitors in
the management of patients with stable CAD were
described in the Antihypertensive Drugs for the Sec-
ondary Prevention of Cardiovascular Events in Patients
With CAD section. They are the HOPE study (16), in
which high-risk individuals, 80% of whom had CAD,
were given an ACE inhibitor (ramipril 10 mg/d), with a
reduction in CVD end points by 20% to 25%; EUROPA
(18), which showed a 20% relative risk reduction in the
primary end point, a composite of cardiovascular death,
MI, or cardiac arrest in patients in subjects with estab-
lished CAD treated with perindopril 8 mg/d versus
placebo; and SAVE (17).
On the other hand, there have been negative studies.
These include PEACE (106), in which patients with sta-
ble CAD and normal or slightly reduced LV function
were randomized to trandolapril (target dose, 4 mg) or
placebo. No difference between the groups was found in
the incidence of the primary composite end point of
cardiovascular death, MI, or coronary revascularization.
Patients in the PEACE trial were at lower risk and were
receiving more aggressive secondary prevention therapy
than those in the HOPE trial. In ALLHAT (96), in which
25% of participants had CAD, there were no signiﬁcant
differences among patients taking chlorthalidone,
amlodipine, and lisinopril in the combined outcomes of
fatal CAD and nonfatal MI (the primary outcome of
the study), in combined CAD (the primary outcome
plus coronary revascularization or hospitalization for
angina), or in all-cause mortality. Soon after the
ALLHAT results were published, the Second Australian
National Blood Pressure Study (ANBP-2) reported theresults of a prospective, open-label study in patients
65 to 84 years of age with hypertension that showed, in
men but not in women, better cardiovascular outcomes
with ACE inhibitors than with diuretic agents despite
similar reductions in BP (175).
4.1.4. Angiotensin Receptor Blockers
ARBs are recommended for all patients with stable angina
who also have hypertension, diabetes mellitus, LV ejec-
tion fraction #40%, or CKD and have indications for, but
are intolerant of, ACE inhibitors (Class I; Level of
Evidence: A) (169). ARBs are indicated during hospitali-
zation and at discharge for STEMI patients who are
intolerant of ACE inhibitors and have HF or an ejection
fraction <0.40 (Class I; Level of Evidence: B) (176). The
combination of ACE inhibitors and ARBs has been used
for the treatment of advanced or persistent HF in the
convalescent or chronic phase after STEMI (177), but the
ONTARGET Study (90) failed to show additive beneﬁt but
with a substantial increase in side effects, so this combi-
nation is not recommended. In the VALUE trial (107),
there was no difference in cardiac mortality and
morbidity in patients with hypertension and high risk of
cardiovascular events who were treated with regimens
based on valsartan versus amlodipine, even though the
BP-lowering effect of amlodipine was greater than that of
valsartan. In VALIANT (91), valsartan was as no more
effective than captopril in patients who were at high risk
for cardiovascular events after MI.
4.1.5. Diuretics
Thiazide diuretics and thiazide-like diuretics reduce
cardiovascular events, as demonstrated most convinc-
ingly in early studies such as the Veterans Administration
studies (93), the MRC Trial (94), and SHEP (95) and in later
studies such as ALLHAT (96). These studies included
subjects with CAD, and it is a reasonable assumption that
diuretics are as effective in the secondary as in the pri-
mary prevention of cardiovascular events.
4.1.6. Nitrates
Long-acting nitrates or CCBs can be prescribed for the
relief of symptoms when b-blockers are contraindicated
or cause unacceptable side effects in patients with stable
angina (Class I; Level of Evidence: B) (169). Long-acting
nitrates or CCBs in combination with b-blockers should
be prescribed for relief of symptoms when initial therapy
with b-blockers is unsuccessful in patients with stable
angina (Class I; Level of Evidence: B). Nitrates should not
be used with phosphodiesterase inhibitors of the silden-
aﬁl type. Hypertension does not affect the use of
long-acting nitrates for the prevention of angina or of
sublingual nitrate preparations for relief of an anginal
J A C C V O L . 6 5 , N O . 1 8 , 2 0 1 5 Rosendorff et al.
M A Y 1 2 , 2 0 1 5 : 1 9 9 8 – 2 0 3 8 Treatment of Hypertension in Patients With CAD
2017attack. Conversely, nitrates have generally not been
shown to be of use in the management of hypertension.
4.2. Recommendations
The management of symptomatic CAD, particularly
angina pectoris, is directed to the relief of the angina
and the prevention of both the progression of CAD and
coronary events. The mainstays of angina treatment are
b-blockers, CCBs, and nitrates. Pharmacological strate-
gies for the prevention of cardiovascular events in these
patients include ACE inhibitors, ARBs, thiazide and
thiazide-like diuretics, b-blockers (particularly after MI),
CCBs, antiplatelet drugs, and drugs for the treatment of
dyslipidemia. The recent ACC Foundation/AHA guide-
lines recommend ACE inhibitors and/or b-blockers, with
the addition of drugs such as thiazide diuretics or CCBs
for the management of high BP in patients with stable
IHD (169).
There are no special contraindications in hypertensive
patients for the use of nitrates, antiplatelet or anticoag-
ulant drugs, or lipid-lowering agents for the management
of angina and the prevention of coronary events, except
that in patients with uncontrolled severe hypertension
who are taking antiplatelet or anticoagulant drugs, BP
should be lowered without delay to reduce the risk of
hemorrhagic stroke.
1. Patients with hypertension and chronic stable angina
should be treated with a regimen that includes:
a) b-blocker in patients with a history of prior MI
b) An ACE inhibitor or ARB if there is prior MI, LV
systolic dysfunction, diabetes mellitus, or CKD; and
c) A thiazide or thiazide-like diuretic (Class I; Level of
Evidence: A).
2. The combination of a b-blocker, an ACE inhibitor or
ARB, and a thiazide or thiazide-like diuretic should
also be considered in the absence of a prior MI, LV
systolic dysfunction, diabetes mellitus, or proteinuric
CKD (Class IIa; Level of Evidence: B).
3. If b-blockers are contraindicated or produce intoler-
able side effects, a nondihydropyridine CCB (such as
diltiazem or verapamil) may be substituted, but not if
there is LV dysfunction (Class IIa; Level of Evidence: B).
4. If either the angina or the hypertension remains uncon-
trolled, a long-actingdihydropyridineCCBcanbeadded to
the basic regimenofb-blocker, ACE inhibitor, and thiazide
or thiazide-like diuretic. The combination of a b-blocker
and either of the nondihydropyridine CCBs (diltiazem
or verapamil) should be used with caution in patients
with symptomatic CAD and hypertension because of
the increased risk of signiﬁcant bradyarrhythmias and
HF(Class IIa; Level of Evidence: B).
5. For patients with stable angina, the BP target is <140/
90 mm Hg. (Class I; Level of Evidence: A). See also theprevious section BP and Treatment Goals. However, a
lower target BP (<130/80 mm Hg) may be considered in
some individuals with CAD, with previous stroke or
transient ischemic attack, or with CAD risk equiva-
lents (carotid artery disease, PAD, abdominal aortic
aneurysm) (Class IIb; Level of Evidence: B).
6. There are no special contraindications in hypertensive
patients for the use of antiplatelet or anticoagulant
drugs, except that in patients with uncontrolled severe
hypertension who are taking antiplatelet or anticoag-
ulant drugs, the BP should be lowered without delay to
reduce the risk of hemorrhagic stroke (Class IIa; Level
of Evidence: C).
5. MANAGEMENT OF HYPERTENSION
IN PATIENTS WITH ACS
Although a major risk factor for CVD, the impact of
hypertension on ACS outcomes has not been well
described. Few data are available on speciﬁc treatments
for hypertension in patients with either STEMI or non–ST-
segment–elevation ACS, including both UA and NSTEMI.
5.1. Prevalence and Impact on Prognosis
Contemporary data from the National Cardiovascular Data
Registry (NCDR) Acute Coronary Treatment and Inter-
vention Outcomes Network (ACTION) Registry–Get With
The Guidelines (GWTG) demonstrate a prevalence of
hypertension of 65.2% among patients with STEMI and
79.2% among those with NSTEMI (ACTION Registry–
GWTG 2012 ﬁrst-quarter report). The prevalence of
hypertension increases notably with age among ACS
patients, with hypertension prevalence rates approxi-
mately double among individuals >75 versus those <45
years of age (178).
The impact of hypertension on outcomes in ACS is
complex. In patients with stabilized ACS enrolled in the
Sibraﬁban Versus Aspirin to Yield Maximum Protection
From Ischemic Heart Events Post-Acute Coronary Syn-
dromes (SYMPHONY) trials, hypertension was an inde-
pendent predictor of death and MI at 90 days (178).
Moreover, hypertension is integrated into the Throm-
bolysis in Myocardial Infarction risk score for UA/
NSTEMI as one of several classic risk factors for CAD,
and the variable of $3 risk factors for CAD was inde-
pendently associated with the composite end point of
mortality and recurrent ischemic events (179). However,
other multivariable risk models have not found hyper-
tension, deﬁned as a “yes/no” categorical variable, to be
independently associated with in-hospital mortality.
Indeed, lower BP more typically emerges as predictive
of poor outcomes in contemporary evaluations. In both
the Global Registry of Acute Coronary Events (GRACE)
(180) and ACTION-GWTG (181) registries, for example,
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10-mm Hg decrease in BP at presentation. In contrast to
the Thrombolysis in Myocardial Infarction risk score for
UA/NSTEMI, in the Thrombolysis in Myocardial Infarc-
tion risk score for STEMI, SBP <100 mm Hg emerged as
a powerful contributor to the model, but hypertension
did not (182). In the Global Use of Strategies to Open
Occluded Coronary Arteries in Acute Coronary Syn-
dromes (GUSTO IIb) and Platelet Glycoprotein IIb/IIIa in
Unstable Angina: Receptor Suppression Using Integrilin
Therapy (PURSUIT) trials (183), a very low SBP (#90
mm Hg) was strongly associated with 48-hour and
30-day mortality, but there was little difference in
mortality between patients who had a high SBP (>140
mm Hg) and those with an SBP in the normal or pre-
hypertensive range (121–140 mm Hg). Even severe hy-
pertension (up to an SBP of 200 mm Hg) appeared to be
protective in the NCDR ACTION analysis of z80,000
patients with MI (181).
Although uncontrolled hypertension does not appear
to signiﬁcantly increase in-hospital mortality in patients
with ACS, it is a major risk factor for intracranial hem-
orrhage and thus remains a relative contraindication to
ﬁbrinolysis (176). When broader bleeding outcomes are
evaluated across the ACS spectrum, a U-shaped associ-
ation between BP and in-hospital bleeding is observed,
with excess bleeding for both patients with hyperten-
sion and those with hypotension. In an analysis from
the Can Rapid Risk Stratiﬁcation of Unstable Angina
Patients Suppress Adverse Outcomes With Early Imple-
mentation of the ACC/AHA Guidelines (CRUSADE) Reg-
istry (184), bleeding rates were lowest in patients
with admission SBP between 120 and 180 mm Hg and
increased progressively with BPs above and below
these ranges. Similarly, in the NCDR ACTION Registry
Bleeding Risk Score, zero points are awarded for an SBP
of 141 to 170 mm Hg on arrival, with 2 points given for
SBP >200 mm Hg and 4 points for SPB #90 mm Hg
(185). In contrast, BP variables did not emerge as inde-
pendently associated with bleeding in the Acute Cath-
eterization and Urgent Intervention Triage Strategy
(ACUITY) and Harmonizing Outcomes With Revascu-
larization and Stents in Acute Myocardial Infarction
(HORIZONS-AMI) trials (186).
These studies have important limitations that make it
difﬁcult to determine the impact of treating hypertension
during an acute ACS episode. All of the data are obser-
vational, and it is likely that residual confounding ex-
plains some, if not most, of the observed adverse
association between lower BP and mortality after ACS,
particularly for BP values within or near the normal range.
In addition, very limited information is available from
these studies on the duration of and long-term disease
burden of hypertension. Despite these limitations, theconsistent associations observed between hypotension
and both mortality and bleeding suggest that avoidance of
hypotension should be an important treatment principle
in ACS patients.
5.2. General Principles of BP Management in the
Patient With ACS
The cornerstone of the management of hypertension in
patients with ACS is the modiﬁcation of the balance
between myocardial oxygen supply and demand. Patients
with ACS are especially vulnerable to perturbations in this
relationship because the development of an ACS is a
clinical manifestation of an alteration in the supply-
demand equation such that ischemia occurs at rest or at
relatively low levels of demand. Although an elevated BP
increases myocardial oxygen demand, rapid and exces-
sive lowering of the DBP has the potential to result in
impairment of coronary blood ﬂow and oxygen supply, as
discussed in the BP Goals section. In addition, patients
with ACS often have vasomotor instability with an
increased tendency to exaggerated responses to antihy-
pertensive therapy.
Because speciﬁc trials of BP lowering have not been
performed in patients with ACS, the selection of antihy-
pertensive agents for use in the patient with ACS should
be focused on selecting drugs that have an established
evidence-base for risk reduction for patients with ACS
independently of BP lowering. These drugs, which
include b-blockers, ACE inhibitors (or ARBs), and, in
selected patients, aldosterone antagonists, should typi-
cally be titrated to full doses before other agents that do
not have an established evidence base are initiated.
Therapeutic targets for BP have not been established
speciﬁcally for patients with ACS. Current guidelines
recommendaBP target of<140/90mmHg and<130/80mmHg
for patients with diabetes mellitus or CKD (1,187), but
this applies more to secondary prevention than the man-
agement of hypertension in the acute phase of MI. The BP
may ﬂuctuate early after ACS; thus, efforts should focus on
pain control and clinical stabilization before BP is speciﬁcally
targeted. Second, the BP should be lowered slowly, and
caution is advised to avoid decreases in DBP to <60 mm Hg
because this may reduce coronary perfusion and worsen
ischemia. A BP target of <130/80 mm Hg at the time of hos-
pital discharge is a reasonable option. In older hypertensive
individuals with wide pulse pressures, lowering SBPmay lead
to very low DBP values, contributing toworseningmyocardial
ischemia.
5.3. Speciﬁc Antihypertensive Agents in ACS
5.3.1. Nitroglycerin
Nitroglycerin has been a cornerstone of therapy for
decades, and in the hypertensive patient with ACS,
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ischemia and pulmonary congestion and is moderately
effective in lowering arterial BP. However, clinical trial
evidence does not support an effect of nitrates on out-
comes in ACS. The Gruppo Italiano per lo Studio della
Sopravvivenza nell’Infarto Miocardico (GISSI)-3 and
International Study of Infarct Survival (ISIS)-4 trials
included almost 80 000 patients with STEMI and found
no difference in mortality with the use of nitrates (7.0%
for those treated versus 7.2% who received placebo in
GISSI-3; 7.3% versus 7.5%, respectively, in ISIS-4)
(188,189). Thus, the ACC/AHA guidelines for STEMI do
not recommend nitroglycerin to reduce events but only
to relieve ischemic pain or acute hypertension or to
manage pulmonary congestion at a Level of Evidence C.
Nitrates should be used with caution in patients with
inferior STEMI and are contraindicated if right ventric-
ular infarction is present because of their effects on
lowering preload. The guidelines caution that nitro-
glycerin should not be used at the expense of agents
with proven beneﬁts on outcomes such as b-blockers or
ACE inhibitors (below), particularly in the convalescent
stage (190).
Experience with nitrates in non–ST-segment–elevation
ACS is largely extrapolated from STEMI because clinical
trials in UA/NSTEMI have been relatively small. Nitro-
glycerin should be ﬁrst administered via the sublingual
route in patients with ACS, which can be followed by
intravenous or topical administration of nitroglycerin or
oral administration of longer-acting nitrate preparations.
Patients treated with nitrates need to be monitored for
potential adverse effects, in particular profound hypo-
tension, which can exacerbate ischemia. Patients at
increased risk include the elderly, individuals who are
volume depleted, or those have used sildenaﬁl within 24
hours or tadalaﬁl within 48 hours. Nitrate tolerance is a
problem even within the ﬁrst 24 hours, and attempts
should be made to minimize this by reducing intravenous
doses and implementing intermittent dosing by non-
intravenous routes once the patient is stable from an
ischemic standpoint.
5.3.2. b-Blockers
b-Blockers are a cornerstone of ACS treatment because of
their ability to reduce both heart rate and BP and thus
myocardial oxygen demand. These agents were among
the ﬁrst therapies demonstrated to reduce infarct size.
b-Blockers reduce early sudden death after MI both via
antiarrhythmic effects and by preventing myocardial
rupture. In patients with STEMI, the long-term beneﬁts of
long-term postdischarge b-blocker administration have
been shown in multiple trials (191). Therefore, routine
discharge use of b-blockers is now a quality performance
measure for patients with ACS.Although b-blockers should be initiated early and
continued for at least 3 years after ACS (176), there has
been increased attention on the appropriate selection of
patients for the use of early intravenous b-blockers after
ACS. Early intravenous b-blockade was shown in a
number of trials performed in the ﬁbrinolytic era to
reduce either mortality or recurrent MI (192,193) and
thus was used as routine therapy in ACS for many
years. However, the Clopidogrel and Metoprolol in
Myocardial Infarction Trial (COMMIT)/Chinese Cardiac
Study (CCC) 2 trial has led to a revision of the recom-
mendations for intravenous b-blocker use in ACS (194).
This study randomized 45,852 AMI patients at presen-
tation to intravenous and then oral b-blockers versus
placebo and assessed the coprimary outcomes of the
composite of death, reinfarction, or cardiac arrest and
death resulting from any cause. At discharge or up to 4
weeks, neither outcome was reduced with metoprolol.
However, the COMMIT trial demonstrated a reduction in
reinfarction (2.0% versus 2.5%) and ventricular ﬁbrilla-
tion (2.5% versus 3.0%), but at the expense of an in-
crease in cardiogenic shock (5.0% versus 3.9%) with
intravenous b-blocker use. The excess risk of shock was
highest in the ﬁrst 2 days of hospitalization, especially
in patients with evidence of hemodynamic instability or
borderline hemodynamics at presentation. In a subset
analysis of patients with hypertension (SBP >140
mm Hg), there were no statistically signiﬁcant differ-
ences between the b-blocker and placebo arms with
respect to the composite primary end point, death or
cardiogenic shock alone, although there was a trend in
favor of the b-blocker. This important study demon-
strated that early intravenous b-blocker therapy should
be used selectively and restricted to patients with sig-
niﬁcant hypertension or tachycardia (i.e., caused by
atrial arrhythmias), those with ongoing ischemia, and
those at low risk for hemodynamic compromise.
Current ACC/AHA guidelines for STEMI and UA/
NSTEMI recommend that oral b-blockade should be
started within the ﬁrst 24 hours, once it is established
that the patient is stable and there are no contraindica-
tions (190,195). The choice of a b-blocker is based on
pharmacokinetic and side-effect criteria and physician
familiarity, but in general, short-acting cardioselective
(b1-selective) b-blockers without intrinsic sympathomi-
metic activity such as metoprolol or bisoprolol are pref-
erable. Carvedilol, which also blocks b2 and a1adrenergic
receptors, has more potent BP-lowering effects than
b1-selective agents and therefore may be a good choice for
patients with ACS and severe hypertension. However, it
should be avoided in patients with obstructive airways
disease because of the effects of b2 antagonism on airway
resistance. Contraindications to the use of b-blockers in
ACS include marked ﬁrst-degree heart block (ECG PR
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block, severe bronchospastic lung disease, decom-
pensated HF, and hypotension. Several meta-analyses
concluded that cardioselective b-blockers do not pro-
duce clinically signiﬁcant adverse respiratory effects in
patients with chronic obstructive pulmonary disease,
suggesting that b-blockers should not be withheld from
these patients (196,197).
5.3.3. Calcium Channel Blockers
In general, CCBs have not been found to be useful in the
setting of acute STEMI. Clinical trials of the rapid-release
form of nifedipine showed an increase in mortality in
patients treated with this agent after MI (198), and there is
currently no role for short-acting nifedipine in clinical
practice. The nondihydropyridine agents diltiazem and
verapamil have also been disappointing in the early-MI
setting and are not recommended for routine use in
patients with STEMI (190,195).
Although several randomized, clinical trials suggested
somewhat greater efﬁcacy for CCBs in non–ST-segment–
elevation ACS (199,200), some of these studies were
performed z30 years ago and predate the era of routine
b-blocker use. Moreover, beneﬁt in these trials was
limited to nonfatal recurrent ischemic events, and
among patients with LV dysfunction, a detrimental ef-
fect on mortality was seen (118,201). Thus, there is no
indication for routine use of CCBs in patients with UA
or NSTEMI. The AHA/ACC guidelines for the manage-
ment of UA and NSTEMI suggest that, in patients with
continuing or frequently recurring ischemia when
b-blockers are contraindicated, a nondihydropyridine
CCB (verapamil or diltiazem) may be used as an alter-
native in the absence of severe LV dysfunction or other
contraindications (195). It is prudent to avoid the use
of verapamil or diltiazem in patients who have LV
dysfunction, and they should not be used together with
b-blockers in that situation.
Evidence for the utility of dihydropyridine CCBs in ACS
is limited. These agents effectively lower BP and may
relieve ischemic symptoms. All CCBs have the potential to
cause hypotension, and the nondihydropyridine CCBs
may precipitate conduction disturbances, particularly
when used in conjunction with b-blockers.
5.3.4. ACE Inhibitors
ACE inhibitors are indicated for most patients with ACS
and are a preferred option for BP management in both
STEMI and non-ST elevation ACS. The data are most
robust for ACE inhibitors in the STEMI population, in
whom most of the trials have been performed, with
results extrapolated to UA/NSTEMI.
In STEMI, ACE inhibitors reduce infarct expansion,
preventing LV remodeling and chamber dilatation (202),which help to prevent downstream sequelae such as
ventricular arrhythmia, HF, or even myocardial rupture.
The GISSI-3, ISIS-4, and CCS-1 trials demonstrated a
beneﬁt from early administration of ACE inhibitors, with
absolute reductions in mortality of 0.8%, 0.5%, and 0.5%
seen as early as 4 weeks after AMI (188,189,203).
A meta-analysis from the ACE Inhibitor Myocardial
Infarction Collaborative Group, which includedz100,000
patients treated within 36 hours of acute MI, found a 7%
lower relative mortality rate at 30 days in patients treated
with ACE inhibitors (204). The beneﬁt was largest in high-
risk groups such as those with HF at presentation (23 lives
saved per 1,000 patients) and those with an anterior MI
(11 lives saved per 1,000 patients). Rates of nonfatal HF
were also reduced, but hypotension and renal dysfunc-
tion were more common.
When ACE inhibitors are started later after MI among
individuals with LV dysfunction and continued long term,
their beneﬁts are even more robust; mortality rates
have been reduced by z20% to 25% in long-term trials
evaluating ACE inhibitors in these high-risk subgroups
(205,206).
5.3.5. Angiotensin Receptor Blockers
ARBs are a useful alternative to ACE inhibitors in
patients with an ACE inhibitor contraindication or
intolerance. The VALIANT trial (91) randomized patients
with LV dysfunction or HF within 10 days after acute MI
to additional therapy with valsartan, captopril, or the
combination of the two. Valsartan was as effective as
captopril for reducing cardiovascular events in these
high-risk patients through 2 years of follow-up. How-
ever, combining valsartan with captopril increased the
rate of adverse events without improving survival. On
the other hand, OPTIMAAL showed a trend toward
increased mortality in patients receiving losartan 50 mg
once daily over patients receiving captopril 50 mg
3 times daily (109). These negative results may have
been attributable to inadequate dosing of losartan. In
summary, because of the larger and more consistent
evidence base for ACE inhibitors, these agents are
preferred over ARBs for patients who can tolerate them,
but ARBs are a ﬁrst-line alternative for ACE inhibitor–
intolerant patients.
5.3.6. Aldosterone Antagonists
Aldosterone, which is incompletely suppressed even
among individuals on high doses of ACE inhibitors,
is thought to contribute to both adverse ventricular
remodeling and myocardial ﬁbrosis after MI. The
EPHESUS trial (112) enrolled >6,600 patients with MI who
had an LV ejection fraction #40% and either signs of HF
or diabetes mellitus. Patients were randomized to the
selective aldosterone inhibitor eplerenone or placebo,
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mortality by 15% and cardiovascular mortality by 17%,
with a reduction in sudden cardiac death of 21%. Of
those enrolled, 87% were receiving ACE inhibitors and
75% were receiving b-blockers, indicating that aldoste-
rone antagonist therapy provides incremental beneﬁt
to these agents. Although spironolactone has not been
studied speciﬁcally in ACS, this agent demonstrated a
signiﬁcant mortality beneﬁt for patients with New York
Heart Association (NYHA) class III or IV HF in the RALES
trial (111), and it is also reasonable to use spironolactone
for patients after ACS who meet EPHESUS criteria.
Aldosterone antagonists should be avoided in patients
with signiﬁcantly elevated serum creatinine levels ($2.5
mg/dL in men, $2.0 mg/dL in women) or elevated
potassium levels ($5.0 mEq/L) because there is a serious
risk of hyperkalemia with the use of these agents
in patients with an estimated creatinine clearance
of <50 mL/min (176). Close clinical and laboratory follow-
up is needed for patients receiving long-term treatment
with aldosterone antagonists to mitigate the occurrence
and complications of hyperkalemia (207).
Mineralocorticoid antagonists are underused among
evidence-based medications after MI. This likely reﬂects
appropriate concerns about the risk for hyperkalemia with
these agents. However, many patients can safely receive
these highly effective and inexpensive agents with care-
ful follow-up.
5.3.7. Diuretics
Although thiazide and thiazide-type diuretics play a
major role in the long-term control of BP, in ACS, diuretics
are used primarily for patients with evidence of increased
ﬁlling pressures, pulmonary venous congestion, or HF.
Particular caution is needed with regard to hypokalemia,
which may precipitate arrhythmias after ACS (6). Loop
diuretics are preferred over thiazide and thiazide-type
diuretics for patients with ACS who have HF (NYHA
class III or IV) or for patients with CKD and an estimated
glomerular ﬁltration rate of <45 mL/min.
5.4. Safety of Anticoagulation in Patients With
Uncontrolled Hypertension
ACS therapy includes several strategies that involve
platelet inactivation and anticoagulation to reduce the
risk of thrombosis and poor clinical outcomes. The rela-
tive efﬁcacy and safety of anticoagulant and antiplatelet
therapy do not differ substantially in patients with
STEMI, NSTEMI, or UA. In the ACS population, these
drugs are most effective when given early. These thera-
pies can lead to major bleeding complications, most
commonly in the gastrointestinal tract and at the site of
femoral access for percutaneous coronary interventions.
Most concerning is that, in the setting of uncontrolledhypertension, the risk of hemorrhagic stroke is increased
(208). This provides another rationale for the aggressive
control of hypertension in patients with ACS.
Rapidly stabilizing patients to facilitate prompt coro-
nary reperfusion is challenging in ACS patients with severe
hypertension. Inherent to the use of medications largely
limiting or disrupting intraluminal thrombus formation is
the potential for severe secondary bleeding. The decision
to pursue an invasive as opposed to a conservative
approach should be based on standard clinical, de-
mographic, and angiographic criteria. Although hyper-
tension per se should not inﬂuence revascularization
decisions other than indirectly in relation to factors such as
renal function, it should be remembered that bleeding
risks are notably higher with uncontrolled hypertension.
5.5. Conclusions
Hypertension will continue to be highly prevalent among
patients with ACS, particularly as the ACS population
ages. The majority will respond to standard methods of
hypertension control. To control BP, speciﬁc agents
should be selected that have an established evidence base
for risk reduction in ACS. These agents include b-blockers,
ACE inhibitors or ARBs, and, in selected patients, aldo-
sterone antagonists. Although nitrates do not change the
natural history of ACS, they are very useful for hyper-
tensive patients with ACS, particularly if there is ongoing
ischemia or pulmonary congestion. Particular care should
be taken to avoid hypotension, with the risk of worsening
myocardial ischemia. The beneﬁts of treating hyperten-
sion in the ACS setting are logical, but perhaps the major
impact on long-term morbidity and mortality depends
on the efﬁcacy of continued outpatient BP control once
effective therapy has been initiated in hospital.
5.6. Recommendations
1. If there is no contraindication to the use of b-blockers,
in patients with ACS, the initial therapy of hyper-
tension should include a short-acting b1-selective
b-blocker without intrinsic sympathomimetic activity
(metoprolol tartrate or bisoprolol). b-Blocker therapy
should typically be initiated orally within 24 hours of
presentation (Class I; Level of Evidence: A). For pa-
tients with severe hypertension or ongoing ischemia,
an intravenous b-blocker (esmolol) can be considered
(Class IIa; Level of Evidence: B). For hemodynamically
unstable patients or when decompensated HF exists,
the initiation of b-blocker therapy should be delayed
until stabilization has been achieved (Class I; Level of
Evidence: A).
2. In patients with ACS and hypertension, nitrates
should be considered to lower BP or to relieve ongoing
ischemia or pulmonary congestion (Class I; Level of
Evidence: C). Nitrates should be avoided in patients
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those with hemodynamic instability. Sublingual or
intravenous nitroglycerin is preferred for initial ther-
apy and can be transitioned later to a longer-acting
preparation if indicated.
3. If there is a contraindication to the use of a b-blocker
or intolerable side effects, then a nondihydropyridine
CCB such as verapamil or diltiazem may be sub-
stituted for patients with ongoing ischemia, provided
that LV dysfunction or HF is not present. If the angina
or hypertension is not controlled on a b-blocker alone,
a longer-acting dihydropyridine CCB may be added
after optimal use of an ACE inhibitor (Class IIa; Level
of Evidence: B).
4. An ACE inhibitor (Class I; Level of Evidence: A) or an
ARB (Class I; Level of Evidence: B) should be added if
the patient has an anterior MI, if hypertension per-
sists, if the patient has evidence of LV dysfunction or
HF, or if the patient has diabetes mellitus. For lower-
risk ACS patients with preserved LV ejection fraction
and no diabetes mellitus, ACE inhibitors can be
considered a ﬁrst-line agent for BP control (Class IIa;
Level of Evidence: A).
5. Aldosterone antagonists are indicated for patients who
are already receiving b-blockers and ACE inhibitors
after MI and have LV dysfunction and either HF or
diabetes mellitus. Serum potassium levels must be
monitored. These agents should be avoided in patients
with elevated serum creatinine levels (‡2.5 mg/dL in
men, ‡2.0 mg/dL in women) or elevated potassium
levels (‡5.0 mEq/L) (Class I; Level of Evidence: A).
6. Loop diuretics are preferred over thiazide and
thiazide-type diuretics for patients with ACS who have
HF (NYHA class III or IV) or for patients with CKD and
an estimated glomerular ﬁltration rate <30 mL/min.
For patients with persistent hypertension not con-
trolled with a b-blocker, an ACE inhibitor, and an
aldosterone antagonist, a thiazide or thiazide-type
diuretic may be added in selected patients for BP
control (Class I; Level of Evidence: B).
7. The target BP is <140/90 mm Hg in patients with ACS
who are hemodynamically stable (Class IIa; Level of
Evidence: C). A BP target of <130/80 mm Hg at the time
of hospital discharge is a reasonable option (Class IIb;
Level of Evidence: C). The BP should be lowered
slowly, and caution is advised to avoid decreases in
DBP to <60 mm Hg because this may reduce coronary
perfusion and worsen ischemia.
6. MANAGEMENT OF HYPERTENSION
IN HF OF ISCHEMIC ORIGIN
Although guidelines from the ACC and the AHA exist for
the treatment of chronic HF (177,209), evidence on whichto base guidelines for the treatment of hypertension in
patients with HF of ischemic origin is limited. On the basis
of information from the Acute Decompensated Heart
Failure National Registry (ADHERE) (210), z75% of
patients hospitalized with HF had hypertension, with
most having SBPs >140 mm Hg. In the Registry to Improve
the Use of Evidence-Based Heart Failure Therapies in the
Outpatient Setting (IMPROVE-HF), >60% of patients seen
in outpatient cardiology practices had a history of
hypertension (211). Additional observational data from
the Duke Databank for Cardiovascular Disease suggest
a similar prevalence of hypertension in patients with
ischemic cardiomyopathy (212).
6.1. Hypertension and HF
Most patients with HF have arterial hypertension (213).
Not only is hypertension an important concomitant dis-
order, but it also contributes to the pathogenesis of both
HF with reduced ejection fraction and HF with preserved
ejection fraction. Hypertension is a major risk factor for
IHD and can lead to the development of HF by causing LV
hypertrophy, impaired cardiac myocyte contractility,
ventricular chamber remodeling, and eventually ventric-
ular dysfunction (214–216).
6.2. Demographics
Elevated levels of DBP and especially SBP are major risk
factors for the development of HF (217,218), and long-
term treatment of both systolic and diastolic hyperten-
sion has been shown to reduce the risk of HF (93,123,219).
The subsequent structural abnormalities that occur in
patients with hypertension, including LV hypertrophy or
MI (e.g., stage B HF), portend a higher number of adverse
cardiovascular outcomes. Patients presenting with HF are
more likely to be older and hypertensive, and more than
half have a normal LV ejection fraction (210,220). Early
investigations of patients with HF such as the Framing-
ham Heart Study cited hypertension as the most frequent
comorbidity; hypertension accounted for 39% of HF cases
in men and 59% in women (217). In a population-based
study in Olmstead County, Minnesota, z50% of patients
presenting with new-onset HF had hypertension (221).
However, recent randomized trials have probably under-
estimated the contribution of hypertension to the devel-
opment and progression of HF, possibly because elderly
patients often are not included in clinical trials of HF. Of
note, HF symptoms are rare in hypertensive individuals
whose BP is well controlled at goal and who have not
sustained an MI (222).
6.3. Hypertension and HF Pathophysiology
Initially, concentric hypertrophy of the LV compensates
for pressure overload and normalizes systolic wall stress.
This adaptive hypertrophy is accompanied by structural
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in gene expression, loss of cardiomyocytes, defective
vascular development, and ﬁbrosis. Thus, the compen-
satory response may transition to HF with progressive
contractile dysfunction (223). In the second stage, CAD
causes myocardial ischemia or MI, which results in HF.
BP falls as HF develops, so the contribution of hyper-
tension to the HF syndrome may be underestimated. The
mechanisms by which increased LV mass leads to
depressed LV ejection fraction remain ill deﬁned. Tradi-
tionally, an MI has been viewed as an obligatory event
in the transition to depressed systolic function. Because
MI occurs in 16% of those who develop depressed
LV ejection fraction compared with 3% of those who
do not, it is an important risk factor (224). However,
there must be other mechanisms because increased LV
mass remains associated with the development of
depressed LV ejection fraction even in patients free of
clinically manifest CAD, including MI. With antihyper-
tensive treatment, the incidence of LV hypertrophy is
reduced by 35%, and the development of HF is reduced by
52% (222).
The mechanisms for the progression from hypertension
to clinical HF with preserved ejection fraction represent
an area of ongoing investigation (225). Potential mecha-
nisms include progressive changes in the myocardial
extracellular matrix and elevation in LV ﬁlling pressures
(226–231).
6.4. CAD and Acute HF
Ischemia may trigger acute pulmonary edema. The ma-
jority of patients with ﬂash pulmonary edema have pre-
served systolic function (210,232–235). These patients are
generally elderly and have severe CAD, typically with 1
occluded vessel and a severely stenosed coronary artery
supplying collateral ﬂow (234–236).
Patients with preserved systolic function and LV
hypertrophy are particularly susceptible to this type of
episode because of their reduced ventricular distensi-
bility, in which small changes in ventricular volume sta-
tus can lead to large changes in ﬁlling pressures. This
abnormal diastolic pressure–volume relationship may
also explain why these patients frequently improve
quickly with diuresis and lowering of BP (237). In terms of
management, the same principles apply when this occurs
in the setting of ischemic cardiomyopathy as in ACS. Refer
to the Management of Hypertension in Patients With ACS
section above.
6.5. Therapeutic Strategies
The therapeutic goals in patients presenting with HF are
to reverse hemodynamic abnormalities, to relieve symp-
toms, and to initiate treatments that will decrease disease
progression and improve survival.6.6. Nonpharmacological Therapies
Sodium restriction is important in the management of
both hypertension and LV dysfunction. Exercise training
(238,239) has been shown to reduce recurrent cardiac
events in patients with LV dysfunction resulting from
ischemic causes. In the Heart Failure: A Controlled Trial
Investigating Outcomes of Exercise Training (HF-
ACTION) study, exercise training was associated with
modest reductions in both all-cause mortality or hospi-
talization and cardiovascular mortality or HF hospitali-
zation after adjustment for highly prognostic baseline
characteristics (240). Exercise training also conferred
signiﬁcant improvements in self-reported health status
compared with usual care (241). For patients with HF,
close medical supervision and careful monitoring of the
BP response to exercise and of the ECG for ventricular
arrhythmias are appropriate (242,243). Other non-
pharmacological therapies, as discussed in the Risk Factor
Reduction section, are also appropriate. These include
management of dyslipidemia, diabetes mellitus, and
obesity, as well as smoking cessation.
6.7. Pharmacological Therapies
When an antihypertensive regimen is devised, optimal
control of BP should remain the primary goal, with the
choice of drugs determined by the concomitant medical
problems (e.g., CAD, diabetes mellitus, or renal disease).
Ultimately, an appropriate antihypertensive regimen
frequently consists of several drugs used in combination.
6.7.1. Diuretics
Diuretic-based antihypertensive therapy has repeatedly
been shown to prevent HF in a wide range of target
populations (244). Thiazide or thiazide-type diuretics are
effective in preventing HF in hypertensive patients (222).
Thiazide or thiazide-type diuretics are the drugs of choice
in patients with mild HF because of a more sustained
natriuretic and diuretic action than loop diuretics,
particularly in those individuals in whom BP control may
be more important than correction of volume overload. In
more severe HF, diuretics are used to reverse volume
overload and associated symptoms. Loop diuretics such
as furosemide and torsemide usually are used because
they produce a greater diuresis for the same degree of
natriuresis; they work even in the presence of renal
impairment, a frequent accompaniment of severe HF; and
their dose-response characteristics are linear and steep,
which allows escalation to high doses. By inducing so-
dium and water loss, diuretics also activate several
adverse mechanisms. There may be a decrease in right
ventricular ﬁlling pressure, with a decrease in stroke
volume and activation of the RAAS and the sympathetic
nervous system (245), effects that would be expected to
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combining diuretic therapy with an ACE inhibitor or
ARB, a b-blocker, and/or an aldosterone antagonist, all
of which have been shown to provide effective therapy
in HF. The Diuretic Optimization Strategies Evaluation
(DOSE) trial in patients with acute HF demonstrated
that a high-dose furosemide strategy was associated
with a nonstatistically signiﬁcant trend toward greater
improvement in patients’ global assessment of symp-
toms but no signiﬁcant difference in creatinine levels.
Although there were greater diuresis with the high-dose
strategy and more favorable outcomes in a few sec-
ondary measures, there was also transient worsening of
renal function (248).
6.7.2. ACE Inhibitors
ACE inhibitors are thought to reduce the remodeling
that occurs after MI (249), to improve ischemic pre-
conditioning (250), to reverse angiotensin II–induced
vasoconstriction and inotropy, to prevent the depletion
of high-energy phosphate stores, to enhance nitric oxide
release through prevention of bradykinin breakdown
(251), and to reduce blood coagulability through the
endothelial release of tissue plasminogen activator
(252). ACE inhibitors have been shown in many trials
to be beneﬁcial in patients with LV dysfunction of
ischemic origin. The Trandolapril Cardiac Evaluation
(TRACE) trial showed a 7% absolute reduction in mor-
tality rate (206,253). In the Acute Infarction Ramipril
Efﬁcacy (AIRE) trial (205), ramipril administered 3 to 7
days after MI reduced the relative mortality risk by 27%
in the total cohort, by 15% in normotensive subjects,
and by 41% in hypertensive subjects, which supports
the particular importance of ACE inhibition in hyper-
tensive patients with LV dysfunction in the post-MI
period. In the Assessment of Treatment With Lisinopril
and Survival (ATLAS) trial, mortality was signiﬁcantly
lower in patients with HF who received a high dose of
lisinopril (32.5–35 mg/d) than in those treated with a
low dose of lisinopril (2.5–5 mg/d) (254). Among patients
with diabetes mellitus or other cardiovascular compli-
cations (16,18), ACE inhibitors have been most notable
with respect to a reduction in the onset of HF and new-
onset diabetes mellitus. However, the message has not
impacted clinicians as well as it should; in the
IMPROVE-HF registry, only z80% of eligible patients
with LV dysfunction were prescribed an ACE inhibitor/
ARB at baseline (211).
6.7.3. Angiotensin Receptor Blockers
Compared with placebo, the ARBs losartan (255) and
irbesartan (256) signiﬁcantly reduced the incidence of HF
in patients with type 2 diabetes mellitus and nephropa-
thy. The VALIANT trial found valsartan to be noninferiorto captopril, although it did not show superiority (61). The
Evaluation of Losartan in the Elderly (ELITE) II trial
compared the efﬁcacy of losartan 50 mg/d with captopril
150 mg/d and found that the rates of all-cause mortality
and sudden death or resuscitated arrests for the losartan
group were not signiﬁcantly different from those for the
captopril group (257). The Valsartan Heart Failure Trial
(Val-HeFT) assessed the efﬁcacy of valsartan at doses up
to 320 mg/d added to standard therapy for reducing
morbidity and mortality in patients with HF (258). Pa-
tients receiving valsartan demonstrated a 13.2% reduction
in the combined end point of cardiovascular mortality and
morbidity compared with patients receiving placebo.
Additional insights into the value of ARBs are provided by
the Candesartan in Heart Failure: Assessment of Reduc-
tion in Mortality and Morbidity (CHARM) program
(259–262). In patients not receiving ACE inhibitors
because of previous intolerance, the use of candesartan
was associated with a signiﬁcant reduction in the primary
composite end point of cardiovascular death and hospital
readmission for HF compared with placebo (259). In the
combination arm of VALIANT, valsartan and captopril
together showed no increased effect over captopril alone
and had a higher incidence of discontinuation because of
adverse effects (91). These results differed from those of
the CHARM-Added trial, in which patients with stable LV
dysfunction beneﬁted from the combination of an ACE
inhibitor and the ARB candesartan (263). The lack of su-
periority of the combination treatment in the VALIANT
trial was likely attributable to the fact that the ACE
inhibitors and ARBs were titrated aggressively at the same
time in the early post-MI period, which resulted in more
side effects. In stable HF patients undergoing an estab-
lished ACE inhibitor therapy, the CHARM trial showed
that the addition of an ARB was well tolerated and
beneﬁcial. This is a strategy that could be used to control
BP if needed.
6.7.4. b-Blockers
b-Blockers lower BP and are negatively inotropic and
chronotropic. They therefore alleviate ischemia and
angina, in addition to lowering BP. The role of b-blockers
in the management of patients with HF is well estab-
lished. The Metoprolol CR/XL Randomized Intervention
Trial in Heart Failure (MERIT-HF) randomized patients
with NYHA class II to IV HF symptoms to receive meto-
prolol succinate versus placebo (264). This trial was
stopped prematurely because of a 34% reduction in
mortality in the metoprolol arm. Four clinical trials of
carvedilol in HF were stopped prematurely because of a
highly signiﬁcant 65% reduction in mortality in patients
treated with carvedilol compared with placebo (265). The
Carvedilol Prospective Randomized Cumulative Survival
(COPERNICUS) trial assessed patients with severe HF
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and who had an LV ejection fraction <25%. Compared
with placebo, carvedilol reduced the mortality risk at
12 months by 38% and the risk of death or hospitalization
for HF by 31% (266). The Multicenter Oral Carvedilol Heart
Failure Assessment (MOCHA) trial demonstrated that this
effect of carvedilol is dose related, with higher doses of
25 mg twice daily showing greater LV functional and
clinical superiority than 6.25 mg twice daily, a dose that
was superior to placebo (267).
Another longer-acting b-blocker, bisoprolol, showed
similar long-term beneﬁt on survival in patients with
HF. The Cardiac Insufﬁciency Bisoprolol Study (CIBIS-II)
showed a 32% reduction in all-cause mortality in
bisoprolol-treated patients with NYHA class III or IV HF
caused by ischemic and nonischemic cardiomyopathy at
a median follow-up of 1.3 years. In that trial, sudden
deaths were reduced by 44% in the bisoprolol-treated
group, whereas pump failure deaths were reduced by
26% (170).
Nebivolol is a b1-selective b-blocker with vasodilating
properties related to nitric oxide modulation. In the Study
of the Effects of Nebivolol Intervention on Outcomes and
Rehospitalization in Seniors with heart failure (SENIORS)
of 2,128 patients $70 years of age with a history of
HF, nebivolol signiﬁcantly decreased all-cause mortality
or cardiovascular hospital admissions over a 21-month
follow-up (268).
Although all 4 of these agents (metoprolol succinate,
carvedilol, bisoprolol, and nebivolol) are beneﬁcial in
patients with HF, the Carvedilol or Metoprolol European
Trial (COMET) demonstrated a 17% greater mortality
reduction in favor of carvedilol compared with metoprolol
tartrate (not the formulation used in MERIT-HF, which
was metoprolol succinate) (264), with mean daily doses of
42 and 85 mg/d, respectively (269). Carvedilol may be
particularly appealing because of its additional a-blocking
properties. There also may be a more favorable effect on
glycemic control.
As a result of these studies, b-blockers are recom-
mended for the long-term management of patients with
hypertension-related LV systolic dysfunction. Patients
should preferably receive 1 of the 4 b-blockers proven
to reduce mortality (carvedilol, metoprolol succinate,
bisoprolol, or nebivolol).
6.7.5. Nitrates and Hydralazine
Nitrate tolerance has limited the ability of long-term
nitrates alone to be effective as antihypertensive agents.
The addition of hydralazine to a nitrate reduces this
tolerance. The African-American Heart Failure Trial
(A-heFT) (270) showed that a combination of a ﬁxed dose
of isosorbide dinitrate and hydralazine provides addi-
tional beneﬁt in African American patients with advancedHF. The trial was stopped early because of a signiﬁcantly
higher mortality rate in the placebo group than in the
group receiving isosorbide dinitrate plus hydralazine
(10.2% versus 6.2%; p ¼ 0.02) (270). Therefore, for African
Americans who require further BP control and relief of
symptoms of HF (NYHA class III or IV), the combination of
hydralazine and isosorbide is recommended together
with ACE inhibitors, b-blockers, and aldosterone antago-
nists (271). Given the lack of randomized trial evidence to
support the prevention of cardiovascular events by the
use of hydralazine in the treatment of primary hyper-
tension (272) and concerns that hydralazine may provoke
angina, monotherapy with hydralazine in IHD is not
recommended.
6.7.6. Aldosterone Receptor Antagonists
Aldosterone has been shown to promote myocardial
ﬁbrosis. RALES reported the effect of adding the com-
petitive aldosterone antagonist spironolactone versus
placebo to standard HF therapy in patients with stage 3
(NYHA class III or IV) HF. There was a 30% reduction in
total mortality with spironolactone (111). Eplerenone, a
selective aldosterone inhibitor, showed similar survival
beneﬁt in the EPHESUS trial. Patients with an LV ejec-
tion fraction of <40% were randomly assigned at 3 to 14
days after MI to therapy with eplerenone or placebo.
During a mean follow-up of 16 months, eplerenone
signiﬁcantly improved mortality by z15% (112). The
EMPHASIS trial supported the beneﬁts of eplerenone in
chronic HF (LV ejection fraction #35%) with mild
symptoms (NYHA class II), in which there was a 37%
reduction in the primary end point of cardiovascular
death or HF hospitalization (113). Although these trials
did not speciﬁcally evaluate patients with hypertension
and HF, the improvement in relative risk with epler-
enone was greater in the subgroup with a history of
hypertension than in normotensive subjects (112), which
suggests that these agents may be particularly beneﬁcial
in patients with hypertension and HF. This class of drug
is especially beneﬁcial in patients with hypokalemia
(273). Electrolytes and renal function should be moni-
tored to prevent hyperkalemia.
6.8. Renal Denervation
The radiofrequency ablation of renal sympathetic nerves
has recently gained attention for its ability to reduce BP
in those with resistant hypertension (274,275). A small
study has demonstrated the ability of renal denervation
to induce LV hypertrophy regression and to improve LV
systolic and diastolic function (276). However, in the
ﬁrst large-scale clinical trial of renal denervation in
patents with resistant hypertension, with an appropriate
control group, namely a sham procedure (Renal Dener-
vation in Patients With Uncontrolled Hypertension
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difference between the 2 groups in the reduction of
SBP, which leaves the future of renal denervation in the
management of hypertension uncertain. The impact of
renal denervation in HF patients is also unclear, and
future randomized trials are needed to clarify its role in
this patient population.
6.9. Goal BP
Healthcare providers should lower both SBP and DBP in
accordance with the recommendations provided in pub-
lished guidelines, including the Seventh Report of the
Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure (3). BP
targets in HF have not been ﬁrmly established, but in
most successful trials, SBP was lowered to the range of 110
to 130 mm Hg. One trial, COPERNICUS (266), demon-
strated beneﬁts of carvedilol in patients with entry
criteria that included SBPs down to 85 mm Hg and who
had a mean pretreatment BP of 123/76 mm Hg, which
suggests that lower BPs (SBP <120 mm Hg) may be
desirable in some patients. Therefore, we make the
recommendation that the target BP in patients with HF
should be <140/90 mm Hg, but we also suggest that
consideration should be given to lowering the BP even
further, to <130/80 mm Hg. Octogenarians should be
checked for orthostatic changes with standing, and an
SBP <130 mm Hg and a DBP <65 mm Hg should be
avoided.
6.10. Drugs to Avoid
Several classes of drugs should be avoided in patients
with ischemic systolic HF with hypertension. Because of
their negative inotropic properties and the increased
likelihood of worsening HF symptoms, nondihydro-
pyridine CCBs such as diltiazem and verapamil should
be avoided (278). The dihydropyridine CCB amlodipine
appeared to be safe in patients with severe systolic HF
in the Prospective Randomized Amlodipine Survival
Evaluation (PRAISE) trial (279), as was felodipine as
supplementary vasodilator therapy in the Vasodilator-
Heart Failure Trial (V-HeFT) III (280). Although cloni-
dine is an effective antihypertensive agent, another
drug in the same class, moxonidine, was associated
with increased mortality in patients with HF (281);
therefore, clonidine also should probably be avoided. In
the ALLHAT trial, the doxazosin arm of the trial was
discontinued because of a 2.04-fold increase in relative
risk of developing HF compared with chlorthalidone
treatment (282). Although there are several caveats
about extrapolating these data to the management of
hypertension in patients with HF, a-blockers should be
used only if other agents used for the management of
hypertension and HF are inadequate to achieve good BPcontrol, and even then, they should be used with
caution. Nonsteroidal anti-inﬂammatory drugs have
been associated with increased BP accompanied by
peripheral edema, weight gain, and worsening renal
function, so they should be used with caution in HF
patients (283,284). Studies of the direct renin inhibitor
aliskiren added to ACE inhibitors or ARBs were stopped
early because of concerns about increased adverse
events, particularly in the setting of renal insufﬁciency
or diabetes mellitus. Ongoing trials of aliskiren in HF
with heightened safety monitoring should help deﬁne
the role, if any, for this agent. Given the lack of ran-
domized trial evidence to support the use of hydral-
azine without a nitrate in the treatment of primary
hypertension and concerns that hydralazine may pro-
voke angina, monotherapy with hydralazine in IHD is
not recommended.
6.11. Recommendations
1. The treatment of hypertension in patients with HF
should include management of risk factors such as
dyslipidemia, obesity, diabetes mellitus, smoking,
and dietary sodium and a closely monitored exercise
program (Class I; Level of Evidence: C).
2. Drugs that have been shown to improve outcomes for
patients with HF with reduced ejection fraction
generally also lower BP. Patients should be treated
with ACE inhibitors (or ARBs), b-blockers (carvedilol,
metoprolol succinate, bisoprolol, or nebivolol), and
aldosterone receptor antagonists (Class I; Level of
Evidence: A).
3. Thiazide or thiazide-type diuretics should be used for
BP control and to reverse volume overload and
associated symptoms. In patients with severe HF
(NYHA class III and IV) or those with severe renal
impairment (estimated glomerular ﬁltration rate <30
mL/min), loop diuretics should be used for volume
control, but they are less effective than thiazide or
thiazide-type diuretics in lowering BP. Diuretics
should be used together with an ACE inhibitor or ARB
and a b-blocker (Class I; Level of Evidence: C).
4. Studies have shown equivalence of beneﬁt of ACE
inhibitors and the ARBs candesartan or valsartan in
HF with reduced ejection fraction. Either class of
agents is effective in lowering BP (Class I; Level of
Evidence: A).
5. The aldosterone receptor antagonists spironolactone
and eplerenone have been shown to be beneﬁcial in
HF and should be included in the regimen if there is
HF (NYHA class II–IV) with reduced ejection fraction
(<40%). One or the other may be substituted for a
thiazide diuretic in patients requiring a potassium-
sparing agent. If an aldosterone receptor antagonist
is administered with an ACE inhibitor or an ARB or in
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should be monitored frequently. These drugs should
not be used, however, if the serum creatinine level
is ‡2.5 mg/dL in men or ‡2.0 mg/dL in women or if the
serum potassium level is ‡5.0 mEq/L. Spironolactone
or eplerenone may be used with a thiazide or
thiazide-like diuretic, particularly in patients with
resistant hypertension (Class I; Level of Evidence: A).
6. Hydralazine plus isosorbide dinitrate should be
added to the regimen of diuretic, ACE inhibitor or
ARB, and b-blocker in African American patients with
NYHA class III or IV HF with reduced ejection fraction
(Class I; Level of Evidence: A). Others may beneﬁt
similarly, but this has not yet been tested.
7. In patients who have hypertension and HF with
preserved ejection fraction, the recommendations
are to control systolic and diastolic hypertension
(Class I; Level of Evidence: A), ventricular rate in the
presence of atrial ﬁbrillation (Class I; Level of Evi-
dence: C), and pulmonary congestion and peripheral
edema (Class I; Level of Evidence: C).
8. Use of b-adrenergic blocking agents, ACE inhibitors,
ARBs, orCCBs inpatientswithHFwithpreservedejection
fraction and hypertension may be effective to minimize
symptoms of HF (Class IIb; Level of Evidence: C).
9. In IHD, the principles of therapy for acute
hypertension with pulmonary edema are similar to
those for STEMI and NSTEMI, as described above
(Class I; Level of Evidence: A). If the patient ishemodynamically unstable, the initiation of these
therapies should be delayed until stabilization of
HF has been achieved.
10. Drugs to avoid in patients with hypertension and
HFwithreducedejectionfractionarenondihydropyridine
CCBs (such as verapamil and diltiazem), clonidine, mox-
onidine, and hydralazine without a nitrate (Class III
Harm; Level of Evidence: B). a-Adrenergic blockers such
as doxazosin should be used only if other drugs for the
management of hypertension and HF are inadequate to
achieve BP control at maximum tolerated doses. Nonste-
roidal anti-inﬂammatory drugs should also be used with
caution in this group, given their effects on BP,
volume status, and renal function (Class IIa; Level
of Evidence: B).
11. The target BP is <140/90 mm Hg, but consideration
can be given to lowering the BP even further, to <130/
80 mm Hg. In patients with an elevated DBP who
have CAD and HF with evidence of myocardial
ischemia, the BP should be lowered slowly. In older
hypertensive individuals with wide pulse pressures,
lowering SBPmay cause very lowDBP values (<60mmHg).
This should alert the clinician to assess carefully any
untoward signs or symptoms, especially those
caused by myocardial ischemia and worsening HF
(Class IIa; Level of Evidence: B). Octogenarians
should be checked for orthostatic changes with
standing, and an SBP <130 mm Hg and a DBP
<65 mm Hg should be avoided.
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